<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8" /><script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function(e,n,t){function r(t){if(!n[t]){var o=n[t]={exports:{}};e[t][0].call(o.exports,function(n){var o=e[t][1][n];return r(o||n)},o,o.exports)}return n[t].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<t.length;o++)r(t[o]);return r}({1:[function(e,n,t){function r(){}function o(e,n,t){return function(){return i(e,[c.now()].concat(u(arguments)),n?null:this,t),n?void 0:this}}var i=e("handle"),a=e(2),u=e(3),f=e("ee").get("tracer"),c=e("loader"),s=NREUM;"undefined"==typeof window.newrelic&&(newrelic=s);var p=["setPageViewName","setCustomAttribute","setErrorHandler","finished","addToTrace","inlineHit","addRelease"],d="api-",l=d+"ixn-";a(p,function(e,n){s[n]=o(d+n,!0,"api")}),s.addPageAction=o(d+"addPageAction",!0),s.setCurrentRouteName=o(d+"routeName",!0),n.exports=newrelic,s.interaction=function(){return(new r).get()};var m=r.prototype={createTracer:function(e,n){var t={},r=this,o="function"==typeof n;return i(l+"tracer",[c.now(),e,t],r),function(){if(f.emit((o?"":"no-")+"fn-start",[c.now(),r,o],t),o)try{return n.apply(this,arguments)}finally{f.emit("fn-end",[c.now()],t)}}}};a("setName,setAttribute,save,ignore,onEnd,getContext,end,get".split(","),function(e,n){m[n]=o(l+n)}),newrelic.noticeError=function(e){"string"==typeof e&&(e=new Error(e)),i("err",[e,c.now()])}},{}],2:[function(e,n,t){function r(e,n){var t=[],r="",i=0;for(r in e)o.call(e,r)&&(t[i]=n(r,e[r]),i+=1);return t}var o=Object.prototype.hasOwnProperty;n.exports=r},{}],3:[function(e,n,t){function r(e,n,t){n||(n=0),"undefined"==typeof t&&(t=e?e.length:0);for(var r=-1,o=t-n||0,i=Array(o<0?0:o);++r<o;)i[r]=e[n+r];return i}n.exports=r},{}],4:[function(e,n,t){n.exports={exists:"undefined"!=typeof window.performance&&window.performance.timing&&"undefined"!=typeof window.performance.timing.navigationStart}},{}],ee:[function(e,n,t){function r(){}function o(e){function n(e){return e&&e instanceof r?e:e?f(e,u,i):i()}function t(t,r,o,i){if(!d.aborted||i){e&&e(t,r,o);for(var a=n(o),u=m(t),f=u.length,c=0;c<f;c++)u[c].apply(a,r);var p=s[y[t]];return p&&p.push([b,t,r,a]),a}}function l(e,n){v[e]=m(e).concat(n)}function m(e){return v[e]||[]}function w(e){return p[e]=p[e]||o(t)}function g(e,n){c(e,function(e,t){n=n||"feature",y[t]=n,n in s||(s[n]=[])})}var v={},y={},b={on:l,emit:t,get:w,listeners:m,context:n,buffer:g,abort:a,aborted:!1};return b}function i(){return new r}function a(){(s.api||s.feature)&&(d.aborted=!0,s=d.backlog={})}var u="nr@context",f=e("gos"),c=e(2),s={},p={},d=n.exports=o();d.backlog=s},{}],gos:[function(e,n,t){function r(e,n,t){if(o.call(e,n))return e[n];var r=t();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,n,{value:r,writable:!0,enumerable:!1}),r}catch(i){}return e[n]=r,r}var o=Object.prototype.hasOwnProperty;n.exports=r},{}],handle:[function(e,n,t){function r(e,n,t,r){o.buffer([e],r),o.emit(e,n,t)}var o=e("ee").get("handle");n.exports=r,r.ee=o},{}],id:[function(e,n,t){function r(e){var n=typeof e;return!e||"object"!==n&&"function"!==n?-1:e===window?0:a(e,i,function(){return o++})}var o=1,i="nr@id",a=e("gos");n.exports=r},{}],loader:[function(e,n,t){function r(){if(!x++){var e=h.info=NREUM.info,n=d.getElementsByTagName("script")[0];if(setTimeout(s.abort,3e4),!(e&&e.licenseKey&&e.applicationID&&n))return s.abort();c(y,function(n,t){e[n]||(e[n]=t)}),f("mark",["onload",a()+h.offset],null,"api");var t=d.createElement("script");t.src="https://"+e.agent,n.parentNode.insertBefore(t,n)}}function o(){"complete"===d.readyState&&i()}function i(){f("mark",["domContent",a()+h.offset],null,"api")}function a(){return E.exists&&performance.now?Math.round(performance.now()):(u=Math.max((new Date).getTime(),u))-h.offset}var u=(new Date).getTime(),f=e("handle"),c=e(2),s=e("ee"),p=window,d=p.document,l="addEventListener",m="attachEvent",w=p.XMLHttpRequest,g=w&&w.prototype;NREUM.o={ST:setTimeout,SI:p.setImmediate,CT:clearTimeout,XHR:w,REQ:p.Request,EV:p.Event,PR:p.Promise,MO:p.MutationObserver};var v=""+location,y={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-1044.min.js"},b=w&&g&&g[l]&&!/CriOS/.test(navigator.userAgent),h=n.exports={offset:u,now:a,origin:v,features:{},xhrWrappable:b};e(1),d[l]?(d[l]("DOMContentLoaded",i,!1),p[l]("load",r,!1)):(d[m]("onreadystatechange",o),p[m]("onload",r)),f("mark",["firstbyte",u],null,"api");var x=0,E=e(4)},{}]},{},["loader"]);</script><script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"bam.nr-data.net","queueTime":0,"licenseKey":"cd1101aa94","agent":"","transactionName":"bgcDMkBZW0NZBkdcWVdNJxNcW0FZVwscV1dKB08QW11CQxYTWlBBZgEOC19dW0QCEVtHU1gG","applicationID":"6369297","errorBeacon":"bam.nr-data.net","applicationTime":1762}</script>
    <title>Prediction in epilepsy | Thinklab</title>
	  <link rel="shortcut icon" href="https://think-lab.s3.amazonaws.com/s/img/favicon.ico" type="image/x-icon" />
    <meta property="og:image" content="https://think-lab.s3.amazonaws.com/s/img" />
    
  <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.6/css/bootstrap.min.css" integrity="sha384-1q8mTJOASx8j1Au+a5WDVnPi2lkFfwwEAa8hDDdjZlpLegxhjVME1fgjWPGmkzs7" crossorigin="anonymous">
  <link rel="stylesheet" href="https://code.jquery.com/ui/1.11.4/themes/smoothness/jquery-ui.css" />

<link rel="stylesheet" href="https://think-lab.s3.amazonaws.com/s/highlightjs/github.css" />
<link rel="stylesheet" href="https://think-lab.s3.amazonaws.com/s/css/css.css" />
<link rel="stylesheet" href="https://think-lab.s3.amazonaws.com/s/css/bootstrap-multiselect.css" />
<!-- <link href='https://fonts.googleapis.com/css?family=Open+Sans:400,700' rel='stylesheet' type='text/css'> -->

    
    
    
    
  
    <meta name="citation_doi" content="10.15363/thinklab.d224">
    <meta name="citation_title" content="Prediction in epilepsy">
    <meta name="citation_online_date" content="Sept. 18, 2016">
    <meta name="citation_author" content="Pouya Khankhanian, Daniel Himmelstein">
    <meta name="citation_journal_title" content="Thinklab">
    <meta name="citation_publisher" content="Thinklab">
  

    


	<!-- GoogleAnalytics -->
	<script>
	(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
	(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
	m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
	})(window,document,'script','//www.google-analytics.com/analytics.js','ga');

	ga('create', 'UA-48550230-1', 'thinklab.org');
	ga('require', 'displayfeatures');
	
	ga('send', 'pageview');

	</script>






</head>
<body >
  <form id="form_action" method="post">
    <input type='hidden' name='csrfmiddlewaretoken' value='JC3hnVSWzcwBOS226QTq2eGyHXj1YAM6' />
</form>

	

	<div class="body-wrapper">

		


<!-- <div style="height:5px;background-image:url('https://think-lab.s3.amazonaws.com/s/img/top-bg.gif');"></div> -->
<div class="gradient">
	<div class="main-centered-div header-container">

<table class="full-width" style="height:60px;"><tr>
	<td style="width:200px;vertical-align:middle;padding-bottom:15px;">
		<a href="/" style="font-weight:normal;color:#212121;"><img src="https://think-lab.s3.amazonaws.com/s/img/logo.png" width="160"></a>
	</td><td style="vertical-align:middle;text-align:left;padding-top:6px;width:100%;padding-left:40px;">
		<ul id="not-search-block"  class="main-header">


			


				<li class="dropdown">
					<a class="dropdown-toggle" data-toggle="dropdown" href="#">Browse <span class="caret"></span></a>
					<ul class="dropdown-menu" role="menu">
						<li><a href="/proposals">Proposals</a></li>
						<li><a href="/projects">Projects</a></li>
						<li><a href="/publications">Article discussion</a></li>
						<li><a href="/discussion">All discussion</a></li>
					</ul>
				</li>
				<li><a href="/leaderboard">Leaderboard</a></li>

			
				<li><a href="/about">About</a></li>
			


		</ul>

    <ul id="search-block" class="main-header" style="display: none; margin-right: 30px;">
        <li class="full-width">
            <form method="get" action="/search">
			<div class="input-group full-width">
				<input name="q" type="text" class="form-control search-input">
			</div>
            </form>
        </li>
    </ul>

	</td><td style="vertical-align:middle;text-align:right;padding-top:6px; min-width: 1%; white-space: nowrap;">
		<ul class="main-header pull-right" style="padding-left: 0;">
    		
                <!-- <li><a href="/login" style="color:silver;">Login</a></li>
                <li style="margin-right:0"><a class="btn btn-default btn-sm btn-upper" href="/signup">Join</a></li> -->
            

        </ul>
    </ul>
	</td>
</tr></table>

<!-- <div id="global-search-div" class="main-centered-div" style="display:none;">
	<input type="text" value="" class="thread-search form-control" placeholder="Search" data-action="/discussion">
</div> -->

	</div>
</div>

		
	  



	  


		

		<div class="dark-head"><div class="main-centered-div">

			

		</div></div>
		
		<div class="main-centered-div" style="margin-top:40px;padding-bottom:340px">
	    

<div style="margin-top:-20px; margin-bottom:20px;">

    <a class="side-box" href="/p/rephetio" style="background-color:#ebfdff;"><div class="side-type">Project:</div> <div class="side-title">Rephetio: Repurposing drugs on a hetnet [rephetio]</div></a><br>



</div>

<table style="margin-top:0px;"><tr>
	<td class="thread-table-content">

		<table class="full-width">
			
<tr class="comment-tr target-hl" id="1" data-comment-id="1355">
  <td class="comment-profile-avatar">
		<a href="/u/pouyakhankhanian"><img class='profile_image photo-medium' src='https://think-lab.s3.amazonaws.com/m/profile/188_medium.jpg' width='60' height='60'></a>
  </td>
	<td class="comment-body">
    <a name="1355"></a>

    

			<h2 class="page-title" style="margin-bottom:5px;margin-top:0px !important;">Prediction in epilepsy</h2>

			<div style="margin-top:5px;color:gray;margin-bottom:20px;font-size:13px;">
				<a style="font-weight:normal;color:#212121" href="/u/pouyakhankhanian"><strong>Pouya Khankhanian</strong></a>
				<span class="is-researcher">Researcher</span>
				&nbsp; <a href="#1" class="light">Sept. 19, 2016</a>
				
			</div>

      

          <hr>
		

    <p>This is a branch of the <a href="https://thinklab.com/discussion/predictions-of-whether-a-compound-treats-a-disease/203" class="citation thread-citation" data-key="10.15363/thinklab.d203">discussion of predictions of hetnet</a>.</p>

		<div style="margin-left:30px;">

      


      <ul class="comment-notes">
				
				
			</ul>

      

		</div>

		


  </td>
</tr>

<tr class="comment-tr target-hl" id="2" data-comment-id="1356">
  <td class="comment-profile-avatar">
		<a href="/u/pouyakhankhanian"><img class='profile_image photo-medium' src='https://think-lab.s3.amazonaws.com/m/profile/188_medium.jpg' width='60' height='60'></a>
  </td>
	<td class="comment-body">
    <a name="1356"></a>

    

      <div class="comment-header">
        <a style="font-weight:bold;color:#212121" href="/u/pouyakhankhanian">Pouya Khankhanian</a>
				<span class="is-researcher">Researcher</span>
				<span class="light">&nbsp;<a href="#2" class="light">Sept. 19, 2016</a>
          
        </span>
      </div>

    

    <h1>Case Discussion of Epilepsy</h1>

<h2>Why epilepsy is a good case disease to study in further detail</h2>

<p>Epilepsy represents a unique case disease for us to evaluate in this project for several reasons. First, it is within the field of expertise of the three clinician collaborators (neurology). Second, a large majority of drugs undergone evaluation for repurposing in epilepsy; this means we largely know which drugs are epileptogenic (exacerbate epilepsy) and which are anti-epileptic (AEDs, drugs given in epilepsy). Thus study of this disease is a good way to validate the predictions of the rephetio project. Third, the distribution of high-scoring predictions in this disease were higher than most. This allows us to characterize the association between prediction score and likelihood of successful drug repurposing (see Daniel's post below for citations). It should be noted that it is unclear if the results seen in epilepsy would necessarily generalizable to other diseases. It would also be prudent to evaluate whether diseases with a large number of high-scoring predictions are the same diseases which had a large number of input disease-drug connections (which is certainly true in epilepsy). Perhaps it is a case of more information in, more information out, and if so it would be nice to characterize this. </p>

<p>I believe it is important for drug-predictions within a given disease to be evaluated by an appropriate clinical specialists. The clinicians collaborating on this project (including myself) are all neurologists by training. I personally find it extremely difficult to evaluate drug predictions for non-neurologic diseases, I would estimate it requires 10x more time for me to research and evaluate each prediction in a non-neurologic disease. Epilepsy is one of the most commonly encountered neurologic diseases in clinic, and I do feel we are fit to evaluate it efficiently and expertly. </p>

<p>Repurposing is more advanced in epilepsy than the majority of other human diseases, we know whether most drugs improve or exacerbate epilepsy. Small animal models of epilepsy are incredibly quick and inexpensive and rather highly applicable to humans. Anti-epileptics work in a dose dependent manner to increase the seizure threshold. The seizure threshold is the amount of electric stimulation that is required to induce seizure. Experimentally, this is done in small animal models by providing graduated increasing electric stimulation until a seizure is attained. The results are generally highly reproducible and thus it requires a very small number of animals. The results are often reproducible between species, further decreasing cost. Furthermore, within the same experiment, one can determine whether a medication would exacerbate epilepsy, these are the drugs that lower the seizure threshold. Given the relatively inexpensive (time and money) nature of pharmacologic testing in epilepsy, drug companies have already attempted drug-repurposing experiments on vast arrays of drugs. Thus, we have a large degree of information about which drugs would possibly work in epilepsy. This makes epilepsy an interesting case to study when looking to validate our repurposing rankings. (there are good reviews cited by Daniel below)</p>

<p>Epilepsy is an outlier for prediction scores. It is the only disease where 1% of drugs had a prediction score higher than 0.35. In the attached pdf, I plotted the distribution of disease scores for each disease, and I'll make a few observations as a digression from epilepsy: hypertension and asthma also have large numbers of drugs with high prediction scores, we see that the highest single predicted scores are not in epilepsy, some diseases such as Paget's disease of bone have a few very highly predicted drugs but overall a low distribution of drug scores. It would also be prudent to evaluate whether diseases with a large number of high-scoring predictions are the same diseases which had a large number of input disease-drug connections (which is certainly true in epilepsy). This is certainly true in hypertension and asthma.</p>

<h2>Epilepsy case study</h2>

<p>The top 100 drug predictions for epielpsy were reviewed (henceforth called "predicted" drugs). This represents the top 7% of drugs predicted for epilepsy (93rd percentile and higher). </p>

<p>The attached powerpoint figure one shows the percent of predicted drugs that are known Anti-Epileptic drugs (AEDs), are known to have antiepileptic activity (raise the seizure threshold), are known to be harmful in epilepsy (lower the seizure threshold), or have no prior evidence ("unknown"). The top 1% of predicted drugs are all known AEDs (17/17, 100%); these have prediction scores greater than 0.35. Of the top 3% of predicted drugs, the overwhelming majority (45/47, 95%) are known AEDs; these have prediction scores greater than 0.09. As we get deeper into the rankings of predicted drugs, we see an increasingly larger percentage of unknown drugs and drugs that lower the seizure threshold. By the 94th percentile, about 40% of the predicted drugs are known AEDs or have known antiepileptic properties, about 47% have unknown epileptic properties, and about 13% are known to lower the seizure threshold; the prediction scores here are around 0.03 to 0.04.</p>

<p>Of the top 100 drugs, 69 are primary AEDs (AEDs that are primarily used in epilepsy), another 7 have known antiepileptic properties. Thus over three quarters (76/100, 76%) are anti-epileptics or known to have antiepileptic properties. An important minority of drugs lower the seizure threshold (15/100, 15%). The remaining drugs are unknown in epilepsy (9/100, 8%). All drugs which are not AEDs are dicussed below:</p>

<h5>Drugs known anti-epileptic properties</h5>

<p>The seven drugs with known anti epileptic properties include three carbonic anhydrase inhibitors (methazolamide, acetazolamide, and diclofenamide), one calcium channel blocker (verapamil), and one sodium channel blocker (Ranolazine). The other two medications are indapamide and modafinil, the mechanism of action of these two drugs in increasing the seizure threshold is unknown.</p>

<h5>Drugs that induce seizures</h5>

<p>The 15 predicted drugs that are known to induce seizures include five are tricyclic antidepressants (TCAs) (amitriptyline, imipramine, nortriptyline, clomipramine, desipramine) three are monoamine oxidate inhibitors (MAOIs) (isocarboxazid, phenelzine, amoxapine), and two are antipsychotics (clozapine and Loxapine) and one is an antihistamine (cyproheptadine). The reason amitriptyline was chosen was explored in the discussion above, and highlights one of the limitations of our method. The TCAs are known to act on GABA-R, which is known to be important in epilepsy (also the TCAs treat migraine and many migraine drugs are also AEDs). The limitation of our method is that it does not differentiate the direction of effect on GABA-R (agonistic versus antagonistic), and thus our method suggests TCAs may treat epilepsy. I suspect the reason MAOIs and antipsychotics were chosen is similar. The other predicted drugs that are known to lower the seizure threshold are antipyrine (an analgesic), dalfampridine (K-channel antagonist), baclofen (inhibits the transmission of both monosynaptic and polysynaptic reflexes at the spinal cord level, possibly by hyperpolarization of primary afferent fiber terminals), and memantine (anti-NMDA). </p>

<h5>Drugs with unknown effect on epilepsy</h5>

<p><strong>Halogenated ethers (Sevoflurane, Desflurane, and Enflurane)</strong>: These are inhaled anesthetics. Some of the halogenated ethers are used in refractory status epilepticus (RSE), such as isoflurane (classified as an AED). Desflurane is also used in RSE, this should likely be reclassified as an AED before we make our final figures/tables. Enflurane and sevoflurane withdrawal can also cause seizures, suggesting that these drugs may have anti-epileptic properties. </p>

<p>Here's the quote form a review <span class="citation">[<a href="https://doi.org/10.1093/bja/aes027" class="citation" data-key="10.1093/bja/aes027">1</a>]</span>: </p>

<blockquote><p>There are multiple case reports of sevoflurane-provoking seizure-like activity, particularly in children <span class="citation">[<a href="https://doi.org/10.1111/j.1460-9592.2004.01538.x" class="citation" data-key="10.1111/j.1460-9592.2004.01538.x">2</a>]</span> and where high concentrations are used in conjunction with hypocapnea <span class="citation">[<a href="https://doi.org/10.1007/BF03022961" class="citation" data-key="10.1007/BF03022961">3</a>]</span>. In high concentration, enflurane exhibits periods of suppression with paroxysmal epileptiform discharges in cats and rats <span class="citation">[<a href="https://doi.org/10.1213/ANE.0b013e3181add06b" class="citation" data-key="10.1213/ANE.0b013e3181add06b">4</a>]</span>. There have been multiple reports of seizure activity in humans after enflurane anaesthesia <span class="citation">[<a href="https://doi.org/10.1213/00000539-199003000-00013" class="citation" data-key="10.1213/00000539-199003000-00013">5</a>, <a href="https://doi.org/10.1097/00000542-198008000-00014" class="citation" data-key="10.1097/00000542-198008000-00014">6</a>]</span>. Isoflurane has well-characterized anticonvulsant properties. Both isoflurane and desflurane can be used in refractory status epilepticus <span class="citation">[<a href="https://doi.org/10.1001/archneur.61.8.1254" class="citation" data-key="10.1001/archneur.61.8.1254">7</a>]</span> [the worst end of the epilepsy spectrum].</p></blockquote>

<p><strong>Glutethimidie</strong>: This is potentially a good choice, it is a GABA agonist anesthetic which makes it a good candidate for repurposing for epilepsy. The prediction score was 0.08 and the percentile was 96th. It is an anesthetic (similar to thalidomide).</p>

<p><strong>Acamprosate</strong>: This drug appears to work in promoting alcohol abstinence by acting as a GABA agonist, which makes it a good candidate for repurposing for epilepsy. The side effect profile is also reasonable. Further, if it is demonstrated to have antiepileptic, it may serve a dual benefit for recovering alcoholics (promoting alcohol abstinence while also perhaps preventing alcohol-associted seizures). The prediction score was 0.03 and the percentile ws 93rd. </p>

<p><strong>Chlorthalidone</strong>: This is a blood pressure medication that acts on Na-Cl channels, potentially related to epilepsy. Other blood pressure medications (albeit of different classes) have been repurposed for epilepsy, as described in the section above). The prediction score was 0.04 and the percentile was 95th. </p>

<p><strong>Phenazopyridine</strong>: a urinary analgesic which is excreted rapidly in the urine and is unlikely to have any clinical effect. </p>

<p><strong>Antineoplastic agents (dabrafenib and bortezomib)</strong>: These are poor choices due to the adverse side effect profiles.</p>

<p>Of note, I did not consider the drug Quinidine barbiurate, as this is a combination drug which is poorly handled by our analysis pipeline.</p>

		<div style="margin-left:30px;">

      


      <ul class="comment-notes">
				
				
			</ul>

      

		</div>

		


  </td>
</tr>

<tr class="comment-tr target-hl" id="3" data-comment-id="1363">
  <td class="comment-profile-avatar">
		<a href="/u/dhimmel"><img class='profile_image photo-medium' src='https://think-lab.s3.amazonaws.com/m/profile/17_medium.jpg' width='60' height='60'></a>
  </td>
	<td class="comment-body">
    <a name="1363"></a>

    

      <div class="comment-header">
        <a style="font-weight:bold;color:#212121" href="/u/dhimmel">Daniel Himmelstein</a>
				<span class="is-researcher">Researcher</span>
				<span class="light">&nbsp;<a href="#3" class="light">Oct. 12, 2016</a>
          
        </span>
      </div>

    

    <h1>Epilepsy literature</h1>

<p>Here are relevant papers I found while learning about the pharmacotherapy of epilepsy.</p>

<ul><li><p>Animal models of epilepsy <span class="citation">[<a href="https://doi.org/10.1358/mf.2009.31.2.1338414" class="citation" data-key="10.1358/mf.2009.31.2.1338414">1</a>, <a href="https://doi.org/10.1016/j.seizure.2011.01.003" class="citation" data-key="10.1016/j.seizure.2011.01.003">2</a>, <a href="https://doi.org/10.1002/0471141755.ph0522s45" class="citation" data-key="10.1002/0471141755.ph0522s45">3</a>, <a href="https://doi.org/10.1038/nn.3934" class="citation" data-key="10.1038/nn.3934">4</a>, <a href="https://doi.org/10.2147/NDT.S50371" class="citation" data-key="10.2147/NDT.S50371">5</a>]</span></p></li><li><p>Antiepileptic drugs <span class="citation">[<a href="https://doi.org/10.1136/bmj.g254" class="citation" data-key="10.1136/bmj.g254">6</a>, <a href="https://doi.org/10.1016/j.nurt.2006.11.009" class="citation" data-key="10.1016/j.nurt.2006.11.009">7</a>, <a href="https://doi.org/10.1016/S1474-4422(07)70215-6" class="citation" data-key="10.1016/S1474-4422(07)70215-6">8</a>, <a href="https://doi.org/10.1038/nrd2997" class="citation" data-key="10.1038/nrd2997">9</a>, <a href="https://doi.org/10.1038/nrd4126" class="citation" data-key="10.1038/nrd4126">10</a>]</span></p></li></ul>

		<div style="margin-left:30px;">

      


      <ul class="comment-notes">
				
				
			</ul>

      

		</div>

		


  </td>
</tr>

<tr class="comment-tr target-hl" id="4" data-comment-id="1366">
  <td class="comment-profile-avatar">
		<a href="/u/pouyakhankhanian"><img class='profile_image photo-medium' src='https://think-lab.s3.amazonaws.com/m/profile/188_medium.jpg' width='60' height='60'></a>
  </td>
	<td class="comment-body">
    <a name="1366"></a>

    

      <div class="comment-header">
        <a style="font-weight:bold;color:#212121" href="/u/pouyakhankhanian">Pouya Khankhanian</a>
				<span class="is-researcher">Researcher</span>
				<span class="light">&nbsp;<a href="#4" class="light">Oct. 16, 2016</a>
          
        </span>
      </div>

    

    <h1>Nomenclature change for the manuscript</h1>

<p>In the manuscript and in the further discussion of this topic, for simplicity and better precision, we chose to call any drug with anti-seizure properties as an anti-ictogenic drug (<code>AIGD</code>), this includes known AEDs as well as drugs which are used as ancillary drugs in the treatment of status epileptics.  We chose to call drugs which lower the seizure threshold ictogenic drugs (<code>IGD</code>).</p>

		<div style="margin-left:30px;">

      


      <ul class="comment-notes">
				
				
			</ul>

      

		</div>

		


  </td>
</tr>

<tr class="comment-tr target-hl" id="5" data-comment-id="1367">
  <td class="comment-profile-avatar">
		<a href="/u/dhimmel"><img class='profile_image photo-medium' src='https://think-lab.s3.amazonaws.com/m/profile/17_medium.jpg' width='60' height='60'></a>
  </td>
	<td class="comment-body">
    <a name="1367"></a>

    

      <div class="comment-header">
        <a style="font-weight:bold;color:#212121" href="/u/dhimmel">Daniel Himmelstein</a>
				<span class="is-researcher">Researcher</span>
				<span class="light">&nbsp;<a href="#5" class="light">Oct. 17, 2016</a>
          
        </span>
      </div>

    

    <h1>Visualizing the top epilepsy predictions</h1>

<p><a href="/u/pouyakhankhanian" class="username">@pouyakhankhanian</a> completed his curation of the top 100 epilepsy predictions (excluding <a href="https://www.drugbank.ca/drugs/DB01346">quinidine barbiurate</a> since it's a combination drug). As <a href="#4">explained above</a>, the classifications were:</p>

<ul><li>AIGD for anti-ictogenic drug</li><li>UNKD for drug with an unknown effect on ictogenesis</li><li>IGD for ictogenic drug</li></ul>

<p>His classifications are available as a <a href="https://github.com/dhimmel/rephetio/blob/127b094076684b40ea35f6e42aca8967afdb9f56/epilepsy/data/PK-curation.tsv">TSV on GitHub</a> (versioned link) and on <a href="https://docs.google.com/spreadsheets/d/1GJvqWp7WkMyboJ49Hts4eSOQCdJc_rcQenmqPLk6Bsw">Google Sheets</a> (unversioned link).</p>

<p>Of the top epilepsy predictions, 77 were AIGDs, 8 were UNKDs, and 15 were IGDs (<a href="https://github.com/dhimmel/rephetio/blob/127b094076684b40ea35f6e42aca8967afdb9f56/epilepsy/epylepsy.ipynb">notebook</a>). Of the 25 disease-modifying epilepsy drugs in PharmacotherapyDB, 23 were in the top predictions. Propofol and vigabatrin were the two that did not make the top 100 predictions and were respectively in the 90.6th and 83.7th percentile for epilepsy predictions.</p>

<p>I created the following visualizations of the top predictions. First, the plot of predicted probability versus compound's rank (ignoring quinidine barbiurate):</p>

<p><img src="https://github.com/dhimmel/rephetio/raw/127b094076684b40ea35f6e42aca8967afdb9f56/epilepsy/figure/epilepsy-labeled.png" alt="Project Rephetio Top Epilepsy Predictions with Compounds Labeled" title="AIGD stands for anti-ictogenic drug; UNKD stands for drug with an unknown effect on ictogenesis; IGD stands for ictogenic drug"></p>

<p>Here is a more complex version of the above plot which uses a sliding window that looks 7 predictions ahead/behind to compute category frequency within the window. The plot shows that top predictions are primarily AIGDs with some UNKDs and IGDs creeping in for lower predictions.</p>

<p><img src="https://github.com/dhimmel/rephetio/raw/127b094076684b40ea35f6e42aca8967afdb9f56/epilepsy/figure/epilepsy-windows.png" alt="Project Rephetio Top Epilepsy Prediction Windows" title="AIGD stands for anti-ictogenic drug; UNKD stands for drug with an unknown effect on ictogenesis; IGD stands for ictogenic drug"></p>

		<div style="margin-left:30px;">

      


      <ul class="comment-notes">
				
<li id="note-272" class="inline-note toggle-parent" data-note-id="272">
	<p><a href="/u/caseygreene">Casey Greene</a>: The axes in this figure are unnatural to me. If you rotated this it would be much easier for me to naturally interpret.
		
	</p>
	
	<table style="display:none;"></table>
</li>

<li id="note-274" class="inline-note toggle-parent" data-note-id="274">
	<p><a href="/u/dhimmel">Daniel Himmelstein</a>: <a href="/u/caseygreene" class="username">@caseygreene</a>, I suspect you're talking about the second (two panel) figure. I agree. Additionally, the second figure adds great complexity with no more information compared to the first. I posted it here, but plan to proceed with only a <a href="https://github.com/dhimmel/rephetio/blob/127b094076684b40ea35f6e42aca8967afdb9f56/epilepsy/figure/epilepsy.png" title="epilepsy.png on dhimmel/rephetio">version of the first image</a> with compound labels removed..
		
	</p>
	
	<table style="display:none;"></table>
</li>

<li id="note-275" class="inline-note toggle-parent" data-note-id="275">
	<p><a href="/u/caseygreene">Casey Greene</a>: Yes - the second portion. I think that it could be interpretable with predicted prob on the y-axis. I do agree that the first is much clearer.
		
	</p>
	
	<table style="display:none;"></table>
</li>

				
			</ul>

      

		</div>

		


  </td>
</tr>

<tr class="comment-tr target-hl" id="6" data-comment-id="1369">
  <td class="comment-profile-avatar">
		<a href="/u/dhimmel"><img class='profile_image photo-medium' src='https://think-lab.s3.amazonaws.com/m/profile/17_medium.jpg' width='60' height='60'></a>
  </td>
	<td class="comment-body">
    <a name="1369"></a>

    

      <div class="comment-header">
        <a style="font-weight:bold;color:#212121" href="/u/dhimmel">Daniel Himmelstein</a>
				<span class="is-researcher">Researcher</span>
				<span class="light">&nbsp;<a href="#6" class="light">Oct. 17, 2016</a>
          
        </span>
      </div>

    

    <h1>Enflurane has established ictogenic properties?</h1>

<p><a href="/u/pouyakhankhanian" class="username">@pouyakhankhanian</a>, I was looking into enflurane and <a href="http://www.epilepsy.com/information/professionals/diagnosis-treatment/procedures-epilepsy-patients/general-anesthetics-6" title="Information For Health Care Professionals: Enflurane">found the following material</a> from the Epilepsy Foundation. The website says the material was adapted from the book <a href="http://www.isbnsearch.org/isbn/9780750672412"><em>Managing epilepsy and co-existing disorders</em></a> from 2002 and was reviewed in 2004.</p>

<blockquote><p>Enflurane is the inhalation agent that anesthesiologists most often avoid when caring for patients with epilepsy, because it lowers seizure threshold. In children and adults with no history of epilepsy, enflurane can cause epileptiform activity with concomitant facial or appendicular myoclonus or generalized tonic-clonic movements <span class="citation">[<a href="https://doi.org/10.1213/00000539-197707000-00010" class="citation" data-key="10.1213/00000539-197707000-00010">1</a>, <a href="https://doi.org/10.1212/wnl.38.6.924" class="citation" data-key="10.1212/wnl.38.6.924">2</a>, <a href="https://doi.org/10.1213/00000539-197001000-00001" class="citation" data-key="10.1213/00000539-197001000-00001">3</a>]</span>. In epilepsy patients, the extent but not the frequency of spike activity on the electrocorticogram is increased <span class="citation">[<a href="https://doi.org/10.1212/wnl.38.6.924" class="citation" data-key="10.1212/wnl.38.6.924">2</a>]</span>. Epileptogenic foci may be activated during epilepsy surgery <span class="citation">[<a href="https://doi.org/10.1213/00000539-199004000-00016" class="citation" data-key="10.1213/00000539-199004000-00016">4</a>, <a href="https://doi.org/10.1097/00000542-198005000-00010" class="citation" data-key="10.1097/00000542-198005000-00010">5</a>]</span>. As the depth of anesthesia is increased with enflurane, the EEG demonstrates high-voltage spikes and spike and slow-wave complexes, the spikes with burst suppression.</p><p>The mechanism of enflurane-induced hyperexcitability in humans is unclear. In animals, enflurane inhibits synapses and stimulates excitatory neuronal transmission in cortical and subcortical areas <span class="citation">[<a href="https://doi.org/10.1016/0013-4694(75)90199-6" class="citation" data-key="10.1016/0013-4694(75)90199-6">6</a>]</span> (page 555).</p><p>Although low enflurane concentrations (1.0–1.5%) administered to a normocarbic patient (arterial partial pressure of carbon dioxide [PaCO2] equals 40 mm Hg) are not frequently associated with seizure activity <span class="citation">[<a href="https://doi.org/10.1097/00000542-197111000-00006" class="citation" data-key="10.1097/00000542-197111000-00006">7</a>]</span>, increasing enflurane concentrations (2–3%) or hyperventilating an anesthetized patient enhances seizure activity. Hyperventilation to a PaCO2 of 20 mm Hg from 40 mm Hg is associated with seizure activity at a 1% lower enflurane concentration. Because hyperventilation is frequently used by neuroanesthesiologists to decrease cerebral blood flow and intracranial pressure, enflurane is avoided when hyperventilation is indicated. An increase in PaCO2 from 40 mm Hg to 60 mm Hg increases the minimum enflurane concentration at which seizures occur by 1% <span class="citation">[<a href="https://doi.org/10.1016/0013-4694(75)90199-6" class="citation" data-key="10.1016/0013-4694(75)90199-6">6</a>]</span>.</p><p>Generalized tonic-clonic and myoclonic seizures can occur within the immediate postoperative period and, potentially, for a few days after enflurane anesthesia. The role of other CNS-active drugs remains uncertain in these cases <span class="citation">[<a href="https://doi.org/10.1097/00000542-197503000-00026" class="citation" data-key="10.1097/00000542-197503000-00026">8</a>]</span>. The convulsant effects may result from enflurane's organic and inorganic nonvolatile fluorinated metabolites <span class="citation">[<a href="https://doi.org/10.1097/00000542-197109000-00007" class="citation" data-key="10.1097/00000542-197109000-00007">9</a>]</span>.</p><p>Although anesthesiologists consider diazepam and thiopental to be anticonvulsants and use them extensively to treat seizure activity, there is some evidence that these drugs may potentiate enflurane-related epileptiform activity in humans <span class="citation">[<a href="https://doi.org/10.1007/bf03006812" class="citation" data-key="10.1007/bf03006812">10</a>]</span>. Nitrous oxide (N2O) does not alter epileptiform activity induced by enflurane <span class="citation">[<a href="https://doi.org/10.1097/00000542-197111000-00006" class="citation" data-key="10.1097/00000542-197111000-00006">7</a>]</span>.</p></blockquote>

<p><a href="/u/pouyakhankhanian" class="username">@pouyakhankhanian</a> do you think this is sufficient evidence to classify enflurane as a IGD? It's likely this information was overlooked due to the poor discoverability of these old studies.</p>

		<div style="margin-left:30px;">

      


      <ul class="comment-notes">
				
<li id="note-278" class="inline-note toggle-parent" data-note-id="278">
	<p><a href="/u/pouyakhankhanian">Pouya Khankhanian</a>: <a href="/u/dhimmel" class="username">@dhimmel</a> I would still classify as unknown because there is conflicting data. For example, it is exhibits periods of suppression with paroxysmal epileptiform discharges in cats and rats, so suppression (anti-epileptic activity) is the norm and the epileptiform discharges (ictogenic activity) is sporadic.
		
	</p>
	
	<table style="display:none;"></table>
</li>

				
			</ul>

      

		</div>

		


  </td>
</tr>

<tr class="comment-tr target-hl" id="7" data-comment-id="1378">
  <td class="comment-profile-avatar">
		<a href="/u/dhimmel"><img class='profile_image photo-medium' src='https://think-lab.s3.amazonaws.com/m/profile/17_medium.jpg' width='60' height='60'></a>
  </td>
	<td class="comment-body">
    <a name="1378"></a>

    

      <div class="comment-header">
        <a style="font-weight:bold;color:#212121" href="/u/dhimmel">Daniel Himmelstein</a>
				<span class="is-researcher">Researcher</span>
				<span class="light">&nbsp;<a href="#7" class="light">Nov. 17, 2016</a>
          
        </span>
      </div>

    

    <h1>Acamprosate for epilepsy</h1>

<p>Epilepsy was the top <a href="http://het.io/repurpose/browse.html?id=DB00659" title="Project Rephetio acamprosate predictions">prediction for acamprosate</a> — an approved treatment for alcohol dependence. From the results of our initial project report <span class="citation">[<a href="/p/rephetio/report" class="citation" data-key="10.15363/thinklab.a7">1</a>, <a href="https://doi.org/10.1101/087619" class="citation" data-key="10.1101/087619">2</a>]</span>:</p>

<blockquote><p>Given this high precision (77%), the 8 compounds of unknown effect are promising repurposing candidates. For example, acamprosate — whose top prediction was epilepsy — is a taurine analog that promotes alcohol abstinence. Support for this repurposing arose from acamprosate's positive modulation of the GABAᴬ receptor and inhibition of the glutamate receptor. If effective against epilepsy, acamprosate could serve a dual benefit for recovering alcoholics who experience seizures from alcohol withdrawal.</p></blockquote>

<p>And from the discussion:</p>

<blockquote><p>Accordingly, we hope certain predictions will spur further research, such as trials to investigate the off-label use of acamprosate for epilepsy.</p></blockquote>

<p>More recently, <a href="/u/pouyakhankhanian" class="username">@pouyakhankhanian</a> identified a 2008 study (Farook et al.) that provides evidence in a single animal model that acamprosate treats epilepsy  <span class="citation">[<a href="https://doi.org/10.1016/j.physbeh.2008.05.020" class="citation" data-key="10.1016/j.physbeh.2008.05.020">3</a>]</span>. The study found that both acampasate and diazepam (positive control) reduced "handling induced convulsions":</p>

<blockquote><p><img src="https://cloud.githubusercontent.com/assets/1117703/20408655/6d95be10-ace4-11e6-8c50-51afaa048f0b.jpg" alt="Figure 2 of https://doi.org/cnfsgc" title="Effects of IP administration of diazepam (0.25, 0.5 and 1 mg/kg) and acamprosate (100, 200 and 300 mg/kg) in male Swiss Webster mice 10 h after the last ‘alcohol + 4-MP’ injection on day 3 in HIC test. Drug solutions or saline (for ‘control’ or ‘alcohol + 4-MP’ treated animals) were administered 30 min prior to the test. Values are expressed as ± S.E.M. ⁎p &lt; 0.05, ⁎⁎p &lt; 0.001 by post hoc Tukey HSD against the alcohol + 4-MP group."></p></blockquote>

<p>In the Hetionet Browser, we <a href="https://neo4j.het.io/browser/?cmd=play&amp;arg=https://neo4j.het.io/guides/rep/DB00659/DOID_1826.html" title="Neo4j Browser for acamprosate-epilepsy">find the following support</a> (only the ten most supportive paths are shown):</p>

<p><img src="https://cloud.githubusercontent.com/assets/1117703/20409718/a8f1e066-ace8-11e6-9ff2-d31fc2d9d7d5.png" alt="Rephetio paths supporting that acamprosate treats epilepsy"></p>

<p>We pick up that acamprosate binds to the GABAA receptor as a positive modular. Furthermore, acamprosate binds to the glutamate receptor as an antagonist. Felbamate and rufinamide — which treat epilepsy — are also glutamate receptor antagonists/inhibitors. The network support provides similar reasoning to the authors of Farook et al.:</p>

<blockquote><p>It was anticipated that diazepam would reduce alcohol withdrawal-induced seizures and this was the case. It is of particular interest that acamprosate had similar anticonvulsant actions with that of diazepam. The underlying mechanism or mechanisms for acamprosate's action are still not well understood. Early on, it was believed that the actions of acamprosate were via its effects on the inhibitory neurotransmitter GABA but this was based primarily on structural analysis with little empirical evidence to support this. Some of the strongest recent evidence supports the actions of acamprosate on glutamate function and/or receptors as the putative mechanism <span class="citation">[<a href="https://doi.org/10.2165/00023210-200519060-00004" class="citation" data-key="10.2165/00023210-200519060-00004">4</a>]</span>.</p></blockquote>

<p>Accordingly, we continue to be excited the use of acamprosate to treat seizures from alcohol withdrawal syndrome.</p>

		<div style="margin-left:30px;">

      


      <ul class="comment-notes">
				
				
			</ul>

      

		</div>

		


  </td>
</tr>

<tr class="comment-tr target-hl" id="8" data-comment-id="1458">
  <td class="comment-profile-avatar">
		<a href="/u/dhimmel"><img class='profile_image photo-medium' src='https://think-lab.s3.amazonaws.com/m/profile/17_medium.jpg' width='60' height='60'></a>
  </td>
	<td class="comment-body">
    <a name="1458"></a>

    

      <div class="comment-header">
        <a style="font-weight:bold;color:#212121" href="/u/dhimmel">Daniel Himmelstein</a>
				<span class="is-researcher">Researcher</span>
				<span class="light">&nbsp;<a href="#8" class="light">Jan. 3, 2017</a>
          
        </span>
      </div>

    

    <h1>Source/target edge contributions in epilepsy predictions</h1>

<p>We've recently developed a new way to assess which nodes or relationships are contributing to a specific prediction. <a href="/u/pouyakhankhanian" class="username">@pouyakhankhanian</a> <a href="https://thinklab.com/discussion/decomposing-the-dwpc-to-assess-intermediate-node-contributions/228#note-297">mentioned</a>:</p>

<blockquote><p>I'd love to see the weight given to various nodes in the top predictions for epilepsy, especially the ones in the top 100 which were not classified as AEDs.</p></blockquote>

<p>For each prediction, <a href="https://thinklab.com/discussion/decomposing-predictions-into-their-network-support/229#3" class="citation thread-citation" data-key="10.15363/thinklab.d229">we calculated</a> source / target edge contributions and deployed them as tables in our Neo4j Browser guides. Here we will evaluate which source edges contributed to the <a href="#5">100 top epilepsy predictions</a>. To do this, we summed source edge contributions across the 100 predictions, replacing the specific source compound with the generic "Compound" (<a href="https://github.com/dhimmel/rephetio/blob/c80cdae446d51d1368f83c7bffff5c94780afc58/epilepsy/partial-DWPC.ipynb">notebook</a>, <a href="https://github.com/dhimmel/rephetio/blob/c80cdae446d51d1368f83c7bffff5c94780afc58/epilepsy/data/source-edge-contributions.tsv">dataset</a>).</p>

<p>In total, 1,667 source edges contributed to the predictions. Here are the top 10:</p>

<table class="table markdown-table"><thead><tr><th>Relationship</th><th>PC</th><th>Contribution</th></tr></thead><tbody><tr><td>Compound—includes—Decreased Central Nervous System Disorganized Electrical Activity</td><td>238</td><td>6.34</td></tr><tr><td>Compound—includes—Benzodiazepines</td><td>52</td><td>3.84</td></tr><tr><td>Compound—binds—GABRA1</td><td>12,385</td><td>2.82</td></tr><tr><td>Compound—resembles—Diazepam</td><td>402</td><td>2.71</td></tr><tr><td>Compound—includes—General Anesthesia</td><td>6</td><td>2.46</td></tr><tr><td>Compound—binds—GABRG2</td><td>8,522</td><td>2.40</td></tr><tr><td>Compound—palliates—multiple sclerosis</td><td>84</td><td>2.16</td></tr><tr><td>Compound—resembles—Amobarbital</td><td>87</td><td>2.13</td></tr><tr><td>Compound—resembles—Clobazam</td><td>227</td><td>2.13</td></tr></tbody></table>

<p>The top edge (<em>Compound—includes—Decreased Central Nervous System Disorganized Electrical Activity</em>) represents a pharmacologic class which overlaps with the indication of epilepsy. We attempted to <a href="https://thinklab.com/discussion/incorporating-drugcentral-data-in-our-network/186#4" class="citation thread-citation" data-key="10.15363/thinklab.d186">avoid including such pharmacologic classes</a>, but our solution was imperfect. Nonetheless, this edge is only responsible for 6% of the top 100 epilepsy predictions. Overall, the predictions drew on a multitude of edges: 22 source edges each contributed over 1%, while 166 contributed over 0.1%. </p>

<p>We also computed the contribution of each target edge to the top epilepsy predictions (<a href="https://github.com/dhimmel/rephetio/blob/c80cdae446d51d1368f83c7bffff5c94780afc58/epilepsy/data/target-edge-contributions.tsv">dataset</a>).<br>In Hetionet v1.0, epilepsy has 531 relationships, of which 375 contributed to at least one prediction. Wanted to get the data up here — a more detailed analysis will follow.</p>

		<div style="margin-left:30px;">

      


      <ul class="comment-notes">
				
				
			</ul>

      

		</div>

		


  </td>
</tr>

<tr class="comment-tr target-hl" id="9" data-comment-id="1464">
  <td class="comment-profile-avatar">
		<a href="/u/dhimmel"><img class='profile_image photo-medium' src='https://think-lab.s3.amazonaws.com/m/profile/17_medium.jpg' width='60' height='60'></a>
  </td>
	<td class="comment-body">
    <a name="1464"></a>

    

      <div class="comment-header">
        <a style="font-weight:bold;color:#212121" href="/u/dhimmel">Daniel Himmelstein</a>
				<span class="is-researcher">Researcher</span>
				<span class="light">&nbsp;<a href="#9" class="light">Jan. 8, 2017</a>
          
        </span>
      </div>

    

    <h1>Chemical similarities between of the top epilepsy predictions</h1>

<p>Hetionet v1.0 includes a <em>Compound–resembles–Compound</em> relationship based on <a href="https://thinklab.com/discussion/calculating-molecular-similarities-between-drugbank-compounds/70" class="citation thread-citation" data-key="10.15363/thinklab.d70">chemical similarity</a>. Resembles relationships were included for compounds with a Dice coefficient ≥ 0.5 <span class="citation">[<a href="https://doi.org/10.15363/thinklab.a7" class="citation hm citation-self" data-key="10.15363/thinklab.a7">1</a>]</span>.</p>

<p>We can use the Hetionet Browser at <a href="https://neo4j.het.io">https://neo4j.het.io</a> to visualize the chemical similarity between the top epilepsy predictions. First, set a Cypher parameter for <code>epilepsy_predictions</code> by executing:</p>

<pre><code class="no-highlight hljs">:param epilepsy_predictions: ['Topiramate', 'Ethotoin', 'Quazepam', 'Alprazolam', 'Primidone', 'Lorazepam', 'Gabapentin', 'Diazepam', 'Methsuximide', 'Estazolam', 'Valproic Acid', 'Triazolam', 'Oxazepam', 'Temazepam', 'Phenytoin', 'Clorazepate', 'Clonazepam', 'Oxcarbazepine', 'Carbamazepine', 'Midazolam', 'Flurazepam', 'Tiagabine', 'Felbamate', 'Chlordiazepoxide', 'Amitriptyline', 'Lacosamide', 'Fosphenytoin', 'Lamotrigine', 'Clobazam', 'Pentobarbital', 'Butabarbital', 'Secobarbital', 'Bromazepam', 'Zonisamide', 'Levetiracetam', 'Talbutal', 'Methylphenobarbital', 'Heptabarbital', 'Nitrazepam', 'Butethal', 'Clotiazepam', 'Fospropofol', 'Sevoflurane', 'Aprobarbital', 'Thiopental', 'Halazepam', 'Phenobarbital', 'Desflurane', 'Fludiazepam', 'Amobarbital', 'Butalbital', 'Prazepam', 'Thiamylal', 'Cinolazepam', 'Glutethimide', 'Isoflurane', 'Adinazolam', 'Quinidine', 'Flunitrazepam', 'Clozapine', 'Ethosuximide', 'Trimethadione', 'Ketamine', 'Imipramine', 'Methazolamide', 'Ketazolam', 'Etomidate', 'Nortriptyline', 'Clomipramine', 'Acetazolamide', 'Enflurane', 'Modafinil', 'Phensuximide', 'Paramethadione', 'Verapamil', 'Chlorthalidone', 'Indapamide', 'Antipyrine', 'Cyproheptadine', 'Isocarboxazid', 'Bortezomib', 'Phenelzine', 'Diclofenamide', 'Pregabalin', 'Hexobarbital', 'Loxapine', 'Dalfampridine', 'Phenazopyridine', 'Zopiclone', 'Ranolazine', 'Amoxapine', 'Baclofen', 'Phenacemide', 'Eszopiclone', 'Desipramine', 'Dabrafenib', 'Rufinamide', 'Memantine', 'Zolpidem', 'Acamprosate']</code></pre>

<p>To see the network: run the following  (with auto-complete turned on):</p>

<pre><code class="no-highlight hljs">MATCH (c:Compound)
WHERE c.name in $epilepsy_predictions
RETURN c</code></pre>

<p><img src="https://cloud.githubusercontent.com/assets/1117703/21754174/c5ceafc6-d5c8-11e6-85da-111d94ec5525.png" alt="epilepsy-prediction-resemblance" title="Chemical similarity network of Project Rephetio top epilepsy predictions"></p>

<p>And to get a table with the number of similar epilepsy predictions for each compound, run:</p>

<pre><code class="no-highlight hljs">MATCH (c0:Compound)-[rel:RESEMBLES_CrC]-(c1:Compound)
WHERE c0.name in $epilepsy_predictions AND c1.name in $epilepsy_predictions
RETURN c0.name AS compound_name, count(rel) AS n_similar_compounds
ORDER BY n_similar_compounds DESC, compound_name</code></pre>

<p>This analysis shows that our top epilepsy predictions include many structurally similar compounds as well as many structurally dissimilar compounds. 29 of the 100 compounds resemble diazepam. Indeed, the benzodiazepines form the largest strongly connected component. The second largest strongly connected component appears to consist of barbiturates, such as phenobarbital which has 14 similar compounds. Halogenated ethers (e.g. enflurane) form a disjoint connected component.</p>

<p>In total, 75 of the 100 compounds resemble at least one other compound. The median number of similar compounds was 6. Finally, 40 compounds had 2 or fewer similar compounds. This analysis shows our top epilepsy predictions pick up clusters of similar compounds, but not to the exclusion of dissimilar compounds.</p>

		<div style="margin-left:30px;">

      


      <ul class="comment-notes">
				
				
			</ul>

      

		</div>

		


  </td>
</tr>

<tr class="comment-tr target-hl" id="10" data-comment-id="1465">
  <td class="comment-profile-avatar">
		<a href="/u/dhimmel"><img class='profile_image photo-medium' src='https://think-lab.s3.amazonaws.com/m/profile/17_medium.jpg' width='60' height='60'></a>
  </td>
	<td class="comment-body">
    <a name="1465"></a>

    

      <div class="comment-header">
        <a style="font-weight:bold;color:#212121" href="/u/dhimmel">Daniel Himmelstein</a>
				<span class="is-researcher">Researcher</span>
				<span class="light">&nbsp;<a href="#10" class="light">Jan. 9, 2017</a>
          
        </span>
      </div>

    

    <h1>Categorizing the top epilepsy predictions</h1>

<p>This post will investigate the categories of compounds in the top 100 epilepsy predictions. For this analysis (<a href="https://github.com/dhimmel/rephetio/blob/898ba3e8dec371af168af14ed316c9a9e49f32bc/epilepsy/3.contribution.ipynb">notebook</a>), We'll use three categorizations of compounds: DrugBank categories, third-level ATC Codes, and DrugCentral pharmacologic classes.</p>

<h2>DrugBank categories</h2>

<p>DrugBank annotates compounds with <a href="https://www.drugbank.ca/categories">categories</a> "based on pharmacological action" <span class="citation">[<a href="https://doi.org/10.1093/nar/gkt1068" class="citation hm " data-key="10.1093/nar/gkt1068">1</a>]</span>. Compounds can have zero or more categories. 84 of the 100 compounds had at least one annotated category. The top eight categories are shown below (<a href="https://github.com/dhimmel/rephetio/blob/898ba3e8dec371af168af14ed316c9a9e49f32bc/epilepsy/data/compounds-categories.tsv">full table here</a>):</p>

<table class="table markdown-table"><thead><tr><th>Category</th><th>Count</th><th>Compounds (in the top epilepsy predictions)</th></tr></thead><tbody><tr><td>Anticonvulsants</td><td>28</td><td>Acetazolamide, Carbamazepine, Clobazam, Clonazepam, Diazepam, Ethosuximide, Ethotoin, Felbamate, Fosphenytoin, Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Methsuximide, Methylphenobarbital, Nitrazepam, Oxcarbazepine, Phenobarbital, Phensuximide, Phenytoin, Pregabalin, Primidone, Thiopental, Tiagabine, Topiramate, Trimethadione, Valproic Acid, Zonisamide</td></tr><tr><td>Hypnotics and Sedatives</td><td>24</td><td>Alprazolam, Butabarbital, Butethal, Chlordiazepoxide, Cinolazepam, Diazepam, Eszopiclone, Etomidate, Fospropofol, Glutethimide, Halazepam, Hexobarbital, Lorazepam, Methylphenobarbital, Midazolam, Nitrazepam, Oxazepam, Pentobarbital, Phenobarbital, Quazepam, Secobarbital, Thiopental, Zolpidem, Zopiclone</td></tr><tr><td>GABA Modulators</td><td>17</td><td>Alprazolam, Bromazepam, Chlordiazepoxide, Clonazepam, Diazepam, Flunitrazepam, Hexobarbital, Methylphenobarbital, Midazolam, Nitrazepam, Oxazepam, Pentobarbital, Phenobarbital, Prazepam, Secobarbital, Thiopental, Triazolam</td></tr><tr><td>Benzodiazepines</td><td>15</td><td>Alprazolam, Bromazepam, Chlordiazepoxide, Cinolazepam, Clobazam, Clonazepam, Clotiazepam, Fludiazepam, Flunitrazepam, Halazepam, Ketazolam, Lorazepam, Quazepam, Temazepam, Triazolam</td></tr><tr><td>Anti-Anxiety Agents</td><td>12</td><td>Alprazolam, Bromazepam, Chlordiazepoxide, Diazepam, Flunitrazepam, Gabapentin, Halazepam, Midazolam, Nitrazepam, Oxazepam, Prazepam, Triazolam</td></tr><tr><td>Barbiturates</td><td>7</td><td>Butabarbital, Butethal, Heptabarbital, Hexobarbital, Pentobarbital, Primidone, Secobarbital</td></tr><tr><td>Antidepressive Agents</td><td>6</td><td>Adinazolam, Desipramine, Isocarboxazid, Lamotrigine, Nortriptyline, Phenelzine</td></tr><tr><td>Adjuvants, Anesthesia</td><td>6</td><td>Chlordiazepoxide, Diazepam, Midazolam, Pentobarbital, Secobarbital, Triazolam</td></tr></tbody></table>

<p>In total, the 100 epilepsy predictions covered 64 DrugBank compounds. Less common categories included stimulants (modafinil), vasodilators (verapamil), potassium channel blockers (dalfampridine), and antipruritics (cyproheptadine).</p>

<h2>Third-level ATC Codes</h2>

<p>The Anatomical Therapeutic Chemical (ATC) Classification System is a classification of drugs produced by the WHOCC <span class="citation">[<a href="https://doi.org/10.4135/9781483349985.n37" class="citation hm " data-key="10.4135/9781483349985.n37">2</a>]</span>. The third-level indicates a therapeutic/pharmacological subgroup. DrugBank compounds are annotated with zero or more ATC codes. 91 of the 100 compounds had at least 1 ATC code. Together, the predictions included 26 third-level ATC codes.</p>

<p>See the <a href="https://github.com/dhimmel/rephetio/blob/898ba3e8dec371af168af14ed316c9a9e49f32bc/epilepsy/data/compounds-third-level-atc-codes.tsv">full table here</a>. The most common codes in the 100 predictions were antiepileptics (25 compounds), hypnotics and sedatives (21 compounds), anxiolytics (12 compounds), "anesthetics, general" (8 compounds), antidepressants (8 compounds), and antiglaucoma preparations and miotics (3 compounds). Less common codes included antiarrhythmics (quinidine), urologicals (phenazopyridine), and antiinfectives (primidone).</p>

<h2>DrugCentral Pharmacologic Classes</h2>

<p>DrugCentral contains pharmacologic classes of six types (Chemical/Ingredient, Mechanism of Action, Physiologic Effect, Established Pharmacologic Class, Pharmacological Action, Application) from 3 publicly-available source (FDA, MeSH, and ChEBI) <span class="citation">[<a href="https://doi.org/10.1093/nar/gkw993" class="citation hm " data-key="10.1093/nar/gkw993">3</a>, <a href="https://doi.org/10.15363/thinklab.d186" class="citation hm citation-self" data-key="10.15363/thinklab.d186">4</a>]</span>. We included <a href="https://thinklab.com/discussion/incorporating-drugcentral-data-in-our-network/186#4" class="citation thread-citation" data-key="10.15363/thinklab.d186">three of the six types</a> in Hetionet v1.0. This analysis however will look at all 6 types.</p>

<p>See the <a href="https://github.com/dhimmel/rephetio/blob/898ba3e8dec371af168af14ed316c9a9e49f32bc/epilepsy/data/compounds-pharmacologic-classes.tsv">full table here</a>. 92 compounds had at least 1 pharmacologic class. Overall, the epilepsy predictions included 206 distinct pharmacologic classes. Due to the large size and diverse nature of this table, it's difficult to quantify. However, it's a good place to work backwards from class to compounds for the epilepsy predictions. For example, you can search for "Monoamine Oxidase Inhibitors" to find the compounds isocarboxazid and phenelzine.</p>

<h2>Conclusion</h2>

<p>The top epilepsy predictions pick up on several drug categories with known anti-ictogenic properties, such as anesthetics, GABA modulators, and of course known anti-epileptics. In addition, the predictions cover categories of drugs that wouldn't traditionally be considered, such as the antimalarial quinidine. In addition, we pick up on classes of AEDs whose primary indication is not epilepsy, such as the carbonic anhydrase inhibitors acetazolamide, diclofenamide, methazolamide, zonisamide that have traditionally been used for glaucoma, but are also effective anti-ictogenic drugs <span class="citation">[<a href="https://doi.org/10.2174/156802607780636726" class="citation hm " data-key="10.2174/156802607780636726">5</a>, <a href="https://doi.org/10.1517/13543776.2013.782394" class="citation hm " data-key="10.1517/13543776.2013.782394">6</a>]</span>. <a href="/u/pouyakhankhanian" class="username">@pouyakhankhanian</a> those are my thoughts, you likely have more!</p>

		<div style="margin-left:30px;">

      


      <ul class="comment-notes">
				
				
			</ul>

      

		</div>

		


  </td>
</tr>

<tr class="comment-tr target-hl" id="11" data-comment-id="1468">
  <td class="comment-profile-avatar">
		<a href="/u/dhimmel"><img class='profile_image photo-medium' src='https://think-lab.s3.amazonaws.com/m/profile/17_medium.jpg' width='60' height='60'></a>
  </td>
	<td class="comment-body">
    <a name="1468"></a>

    

      <div class="comment-header">
        <a style="font-weight:bold;color:#212121" href="/u/dhimmel">Daniel Himmelstein</a>
				<span class="is-researcher">Researcher</span>
				<span class="light">&nbsp;<a href="#11" class="light">Jan. 10, 2017</a>
          
        </span>
      </div>

    

    <h1>Quantifying the biological evidence behind the top epilepsy predicitons</h1>

<p>In a <a href="#8">previous comment</a>, I introduced aggregating individual path contributions for all 100 top epilepsy predictions. This post will go into further depth on the topic — specifically, we're trying to understand what biomedical evidence in Hetionet supports our top epilepsy predictions. These analyses were performed by <a href="https://nbviewer.jupyter.org/github/dhimmel/rephetio/blob/898ba3e8dec371af168af14ed316c9a9e49f32bc/epilepsy/3.contribution.ipynb">this notebook</a>.</p>

<h2>Contributions by metapath</h2>

<p>First, we'll aggregate path contributions by their metapath. Here we're asking what types of paths contributed to the top epilepsy predictions (<a href="https://github.com/dhimmel/rephetio/blob/898ba3e8dec371af168af14ed316c9a9e49f32bc/epilepsy/data/metapath-contributions.tsv">source</a>).</p>

<table class="table markdown-table"><thead><tr><th>Metapath</th><th>Paths</th><th>Contribution</th></tr></thead><tbody><tr><td>CbGbCtD</td><td>6,358</td><td>20.624</td></tr><tr><td>CrCtD</td><td>160</td><td>18.266</td></tr><tr><td>CbGaD</td><td>562</td><td>17.568</td></tr><tr><td>CiPCiCtD</td><td>322</td><td>15.051</td></tr><tr><td>CrCrCtD</td><td>2,559</td><td>11.902</td></tr><tr><td>CpDpCtD</td><td>212</td><td>5.3199</td></tr><tr><td>CcSEcCtD</td><td>117,720</td><td>4.4182</td></tr><tr><td>CbGpPWpGaD</td><td>248,740</td><td>3.9824</td></tr><tr><td>CbGeAlD</td><td>10,522</td><td>1.6028</td></tr><tr><td>CtDrD</td><td>5</td><td>1.13</td></tr><tr><td>CrCbGaD</td><td>5,788</td><td>0.13895</td></tr><tr><td>CbGdCrCtD</td><td>8</td><td>0.001348</td></tr></tbody></table>

<p>Note that the total contribution of all paths across all predictions is 100. So for example, 6,358 <em>Compound–binds–Gene–binds–Compound–treats–Disease</em> (CbGbCtD) paths provide 20.6% of the support for the top epilepsy predictions combined. Illustrating the importance of integrative drug repurposing in epilepsy, 10 different metapaths each provided at least 1% of the total support.</p>

<p>Next, we aggregated metapath contributions by their source metaedge. This analysis asks what types of edges inform the algorithm about compounds for treating epilepsy?</p>

<table class="table markdown-table"><thead><tr><th>Source Metaedge</th><th>Paths</th><th>Contribution</th></tr></thead><tbody><tr><td>Compound—binds—Gene</td><td>266,192</td><td>43.78</td></tr><tr><td>Compound—resembles—Compound</td><td>8,507</td><td>30.31</td></tr><tr><td>Compound—includes—Pharmacologic Class</td><td>322</td><td>15.05</td></tr><tr><td>Compound—palliates—Disease</td><td>212</td><td>5.32</td></tr><tr><td>Compound—causes—Side Effect</td><td>117,724</td><td>4.42</td></tr><tr><td>Compound—treats—Disease</td><td>5</td><td>1.13</td></tr></tbody></table>

<p>We see that 43.8% of the support for predicted epilepsy treatments came from their targeted genes. We see that our method is leveraging many different types of information on compounds to make its epilepsy predictions. Note that which diseases a compound treats (excluding epilepsy of course) did not play a major role, as we <a href="https://thinklab.com/discussion/our-hetnet-edge-prediction-methodology-the-modeling-framework-for-project-rephetio/210#4" class="citation thread-citation" data-key="10.15363/thinklab.d210">suppressed</a> many of these features <span class="citation">[<a href="https://doi.org/10.15363/thinklab.d215" class="citation citation-self" data-key="10.15363/thinklab.d215">1</a>]</span>. </p>

<p>If we aggregate instead by target metaedge, we can understand what aspects of epilepsy our algorithm leveraged:</p>

<table class="table markdown-table"><thead><tr><th>Target Metaedge</th><th>Paths</th><th>Contribution</th></tr></thead><tbody><tr><td>epilepsy syndrome—treats—Compound</td><td>127,343</td><td>75.58</td></tr><tr><td>epilepsy syndrome—associates—Gene</td><td>255,092</td><td>21.69</td></tr><tr><td>epilepsy syndrome—localizes—Anatomy</td><td>10,522</td><td>1.60</td></tr><tr><td>epilepsy syndrome—resembles—Disease</td><td>5</td><td>1.13</td></tr></tbody></table>

<p>In the context of top predictions, our algorithm understood epilepsy primarily by its known treatments (76%) and genetic associations (22%).</p>

<h2>Contribution by target gene groups</h2>

<p>43.8% of the support for epilepsy predictions came from paths that start with a <em>Compound—binds—Gene</em> metaedge. Let's dig deeper here. Are all the compounds binding to the same family or functional group of genes? To answer this question, I aggregated all paths by the gene node in their source relationship. Paths without a gene as the first intermediate node dropped out.</p>

<p>However, an issue arose where many genes belonged to the same family or functional group, such as encoding proteins for the same receptor. For example, see the following symbol to name mappings:</p>

<ul><li><em>GRIA2</em>: "glutamate receptor, ionotropic, AMPA 2"</li><li><em>GRIK2</em>: "glutamate receptor, ionotropic, kainate 2"</li><li><em>GRIN2A</em>: "glutamate receptor, ionotropic, N-methyl D-aspartate 2A"</li><li><em>GRM5</em>: "glutamate receptor, metabotropic 5"</li></ul>

<p>To resolve this issue, I truncated gene names at their first comma not in parentheses. Note that this this approach does not appear to work with current HGNC gene names, but does appear to work for our version of Entrez Gene <span class="citation">[<a href="https://doi.org/10.15363/thinklab.d34" class="citation citation-self" data-key="10.15363/thinklab.d34">2</a>, <a href="https://doi.org/10.5281/zenodo.45524" class="citation citation-figure" data-key="10.5281/zenodo.45524">3</a>]</span>. I also truncated gene names after the word "receptor" or "anhydrase". I also investigated grouping genes by their <a href="https://thinklab.com/discussion/using-entrez-gene-as-our-gene-vocabulary/34#13" class="citation thread-citation" data-key="10.15363/thinklab.d34">HGNC family</a>, but this became complicated since genes can belong to many families with varying levels of specificity.</p>

<p>The top 8 gene groups — all groups with contribution &gt; 1% — are shown below (<a href="https://github.com/dhimmel/rephetio/blob/3f3e6ecb7a9b8bb64cde76ac8176d31fc19fdc42/epilepsy/data/source-edge-binds-contributions.tsv">full table here</a>):</p>

<table class="table markdown-table"><thead><tr><th>Gene Group</th><th>Paths</th><th>Contribution</th><th>Genes</th></tr></thead><tbody><tr><td>gamma-aminobutyric acid (GABA) A receptor</td><td>91,967</td><td>15.329</td><td>GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3</td></tr><tr><td>cytochrome P450</td><td>34,323</td><td>5.5857</td><td>CYP11A1, CYP11B1, CYP11B2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A43, CYP3A5, CYP3A7, CYP4A11, CYP4B1</td></tr><tr><td>sodium channel</td><td>8,771</td><td>4.5576</td><td>SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A</td></tr><tr><td>glutamate receptor</td><td>11,441</td><td>3.8415</td><td>GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRM5</td></tr><tr><td>calcium channel</td><td>4,579</td><td>2.665</td><td>CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNB1, CACNB2, CACNB3, CACNB4</td></tr><tr><td>carbonic anhydrase</td><td>5,483</td><td>2.4512</td><td>CA1, CA10, CA11, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9</td></tr><tr><td>cholinergic receptor</td><td>19,114</td><td>2.0839</td><td>CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA4, CHRNA7</td></tr><tr><td>potassium channel</td><td>7,958</td><td>1.4308</td><td>KCNA1, KCNA10, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7, KCNB1, KCNB2, KCNC1, KCNC2, KCNC3, KCNC4, KCND1, KCND2, KCND3, KCNE1, KCNF1, KCNG1, KCNG2, KCNG3, KCNG4, KCNH1, KCNH2, KCNH3, KCNH4, KCNH5, KCNH6, KCNH7, KCNH8, KCNJ11, KCNJ8, KCNK1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK6, KCNK9, KCNN4, KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5, KCNV1, KCNV2</td></tr></tbody></table>

<p>We see that 15.3% of the support for the top epilepsy predictions is based on the predicted compound binding to GABAᴀ receptors <span class="citation">[<a href="https://doi.org/10.1046/j.1528-1157.2001.042suppl.3008.x" class="citation " data-key="10.1046/j.1528-1157.2001.042suppl.3008.x">4</a>]</span>. In addition, 5.6% can be attributed to compounds binding cytochrome P450 proteins, which metabolize many drugs and are important for the pharmacokinetics of AEDs <span class="citation">[<a href="https://doi.org/10.2174/157015910792246254" class="citation " data-key="10.2174/157015910792246254">5</a>]</span>. Compounds that bound sodium channels — an established therapeutic target for epilepsy <span class="citation">[<a href="https://doi.org/10.2174/156802612800229206" class="citation " data-key="10.2174/156802612800229206">6</a>]</span> — contributed 4.6%. The list continues, attesting to the ability of our method to detect and leverage bonafide targets for treating epilepsy <span class="citation">[<a href="https://doi.org/10.2174/1568026053386962" class="citation " data-key="10.2174/1568026053386962">7</a>, <a href="https://doi.org/10.1016/j.nurt.2006.11.010" class="citation " data-key="10.1016/j.nurt.2006.11.010">8</a>, <a href="https://doi.org/10.1038/nrn1430" class="citation " data-key="10.1038/nrn1430">9</a>, <a href="https://doi.org/10.1016/j.seizure.2010.10.027" class="citation " data-key="10.1016/j.seizure.2010.10.027">10</a>]</span>. For example, the next genes groups were glutamate receptors <span class="citation">[<a href="https://doi.org/10.1093/med/9780199746545.003.0010" class="citation " data-key="10.1093/med/9780199746545.003.0010">11</a>]</span>, the calcium channel <span class="citation">[<a href="https://doi.org/10.1007/0-387-27526-6_13" class="citation " data-key="10.1007/0-387-27526-6_13">12</a>, <a href="https://doi.org/10.1111/j.1528-1167.2010.02797.x" class="citation " data-key="10.1111/j.1528-1167.2010.02797.x">13</a>]</span>, carbonic anhydrases <span class="citation">[<a href="https://doi.org/10.2174/156802607780636726" class="citation " data-key="10.2174/156802607780636726">14</a>, <a href="https://doi.org/10.1517/13543776.2013.782394" class="citation " data-key="10.1517/13543776.2013.782394">15</a>]</span>, cholinergic receptors <span class="citation">[<a href="https://doi.org/10.2174/1568007023339193" class="citation " data-key="10.2174/1568007023339193">16</a>, <a href="https://doi.org/10.1007/s11064-007-9429-3" class="citation " data-key="10.1007/s11064-007-9429-3">17</a>]</span>, and the potassium channel <span class="citation">[<a href="https://doi.org/10.1101/cshperspect.a022871" class="citation " data-key="10.1101/cshperspect.a022871">18</a>, <a href="https://doi.org/10.1517/14740338.2013.823399" class="citation " data-key="10.1517/14740338.2013.823399">19</a>]</span>.</p>

<p>In total, 90 gene groups provided support, 11 of which contributed over 0.5%.</p>

<h2>Contribution by Side Effect node</h2>

<p>117,720 <em>CcSEcCtD</em> paths provided 4.4% of the support for our epilepsy predictions. These paths traverse 1,137 specific side effects.  If we restrict ourselves to <em>Compound—causes—Side Effect</em> source edge contributions, we can rank side effects by their aggregate contribution to our epilepsy predictions. The top five side effects reflect known adverse adverse of AEDs. In order, this approach highlights Ataxia (0.069% of total support) <span class="citation">[<a href="https://doi.org/10.1136/jnnp.2006.100222" class="citation " data-key="10.1136/jnnp.2006.100222">20</a>]</span>, Nystagmus (0.049%) <span class="citation">[<a href="https://doi.org/10.1016/j.ebcr.2015.07.003" class="citation " data-key="10.1016/j.ebcr.2015.07.003">21</a>]</span>, Diplopia (0.045%) <span class="citation">[<a href="https://doi.org/10.1016/S1059-1311(03)00082-7" class="citation " data-key="10.1016/S1059-1311(03)00082-7">22</a>]</span>, Somnolence (0.044%) <span class="citation">[<a href="https://doi.org/10.1016/S1388-2457(00)00411-9" class="citation " data-key="10.1016/S1388-2457(00)00411-9">23</a>]</span>, and Vomiting (0.043%) <span class="citation">[<a href="https://doi.org/10.1016/j.seizure.2010.12.011" class="citation " data-key="10.1016/j.seizure.2010.12.011">24</a>]</span>.</p>

<h2>Contributions by Anatomy node</h2>

<p>Finally, Hetionet contained <em>Disease–localizes–Anatomy</em> relationships automatically generated from <a href="https://thinklab.com/discussion/mining-knowledge-from-medline-articles-and-their-indexed-mesh-terms/67#5" class="citation thread-citation" data-key="10.15363/thinklab.d67">MEDLINE co-occurrence</a>. Epilepsy ended having relationships with 24 anatomies (anatomical structures, e.g. tissues) that contributed to the predictions through <em>Compound–binds–Gene–expresses–Anatomy–localizes–Disease</em> (CbGeAlD) paths. By aggregating CbGeAlD paths by their Anatomy node, we computed <a href="https://github.com/dhimmel/rephetio/blob/898ba3e8dec371af168af14ed316c9a9e49f32bc/epilepsy/data/anatomy-node-contributions.tsv">the contribution</a> of each anatomy to our epilepsy predictions. What caught my eye is that anatomies that are more relevant to parthenogenesis and drug efficacy were near the top of the list. Examples include the telencephalon, forebrain, and nervous system. The anatomies that are related to epilepsy but primarily through its symptoms were near the bottom of the list. These examples include the tongue and meninx. This particular observation isn't well controlled, but I wanted to mention it as a future avenue of research.</p>

<h2>Conclusion</h2>

<p>Our top epilepsy predictions derive from a diverse set of supporting evidence that is supported by the current understanding of epilepsy. Aggregating path contributions allows us to evaluate the overall contribution of each network component, for a given context.</p>

		<div style="margin-left:30px;">

      


      <ul class="comment-notes">
				
				
			</ul>

      

		</div>

		


  </td>
</tr>

    		
		</table>

    

    &nbsp;<br>
    <!-- <a class="btn btn-primary btn-lg" href="/signup?next=/discussion/prediction-in-epilepsy/224&suppress_message=1" style>Join to Reply</a> -->


		<table class="references table-td-5" style="display:none;"><tr style=&#39;display:none;&#39;><td><a href='/doi/10.15363/thinklab.d203' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>1.</div></td><td><div class='doi-body' data-key='10.15363/thinklab.d203'><a href='/d/203' class='pub-title'>Predictions of whether a compound treats a disease</a><div class='pub-body'>Daniel Himmelstein, Chrissy Hessler, Pouya Khankhanian (2016) <i>Thinklab</i>. doi:<a href='https://doi.org/10.15363/thinklab.d203'>10.15363/thinklab.d203</a></div></div></td></tr><tr><td><a href='/doi/10.1093/bja/aes027' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>2.</div></td><td><div class='doi-body' data-key='10.1093/bja/aes027'><a href='/doi/10.1093/bja/aes027' class='pub-title'>Anaesthesia and epilepsy</a><div class='pub-body'>A. Perks, S. Cheema, R. Mohanraj (2012) <i>British Journal of Anaesthesia</i>. doi:<a class='pub-doi' href='https://doi.org/10.1093/bja/aes027'>10.1093/bja/aes027</a></div></div></td></tr><tr><td><a href='/doi/10.1111/j.1460-9592.2004.01538.x' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>3.</div></td><td><div class='doi-body' data-key='10.1111/j.1460-9592.2004.01538.x'><a href='/doi/10.1111/j.1460-9592.2004.01538.x' class='pub-title'>Sevoflurane and epileptiform EEG changes</a><div class='pub-body'>ISABELLE CONSTANT, ROBERT SEEMAN, ISABELLE MURAT (2005) <i>Pediatric Anesthesia</i>. doi:<a class='pub-doi' href='https://doi.org/10.1111/j.1460-9592.2004.01538.x'>10.1111/j.1460-9592.2004.01538.x</a></div></div></td></tr><tr><td><a href='/doi/10.1007/BF03022961' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>4.</div></td><td><div class='doi-body' data-key='10.1007/BF03022961'><a href='/doi/10.1007/BF03022961' class='pub-title'>Repetitive generalized seizure-like activity during emergence from sevoflurane anesthesia</a><div class='pub-body'>Arvind Mohanram, Vikram Kumar, Zafar Iqbal, Sandeep Markan, Paul S. Pagel (2007) <i>Canadian Journal of Anesthesia/Journal canadien d&#39;anesthésie</i>. doi:<a class='pub-doi' href='https://doi.org/10.1007/BF03022961'>10.1007/BF03022961</a></div></div></td></tr><tr><td><a href='/doi/10.1213/ANE.0b013e3181add06b' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>5.</div></td><td><div class='doi-body' data-key='10.1213/ANE.0b013e3181add06b'><a href='/doi/10.1213/ANE.0b013e3181add06b' class='pub-title'>The Electrocortical Effects of Enflurane: Experiment and Theory</a><div class='pub-body'>James W. Sleigh, Jeannette A. Vizuete, Logan Voss, Alistair Steyn-Ross, Moira Steyn-Ross, Charles J. Marcuccilli, Anthony G. Hudetz (2009) <i>Anesthesia &amp; Analgesia</i>. doi:<a class='pub-doi' href='https://doi.org/10.1213/ANE.0b013e3181add06b'>10.1213/ANE.0b013e3181add06b</a></div></div></td></tr><tr><td><a href='/doi/10.1213/00000539-199003000-00013' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>6.</div></td><td><div class='doi-body' data-key='10.1213/00000539-199003000-00013'><a href='/doi/10.1213/00000539-199003000-00013' class='pub-title'>Pro-and Anticonvulsant Effects of Anesthetics (Part I)</a><div class='pub-body'>Paul A. Modica, Rene Tempelhoff, Paul F. White (1990) <i>Anesthesia &amp; Analgesia</i>. doi:<a class='pub-doi' href='https://doi.org/10.1213/00000539-199003000-00013'>10.1213/00000539-199003000-00013</a></div></div></td></tr><tr><td><a href='/doi/10.1097/00000542-198008000-00014' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>7.</div></td><td><div class='doi-body' data-key='10.1097/00000542-198008000-00014'><a href='/doi/10.1097/00000542-198008000-00014' class='pub-title'>Postoperative Seizure Activity Following Enflurane Anesthesia</a><div class='pub-body'>Micheal Kruczek, Maurice S. Albin, Steven Wolf, John M. Bertoni (1980) <i>Anesthesiology</i>. doi:<a class='pub-doi' href='https://doi.org/10.1097/00000542-198008000-00014'>10.1097/00000542-198008000-00014</a></div></div></td></tr><tr><td><a href='/doi/10.1001/archneur.61.8.1254' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>8.</div></td><td><div class='doi-body' data-key='10.1001/archneur.61.8.1254'><a href='/doi/10.1001/archneur.61.8.1254' class='pub-title'>Treatment of Refractory Status Epilepticus With Inhalational Anesthetic Agents Isoflurane and Desflurane</a><div class='pub-body'>Seyed M. Mirsattari, Michael D. Sharpe, G. Bryan Young (2004) <i>Archives of Neurology</i>. doi:<a class='pub-doi' href='https://doi.org/10.1001/archneur.61.8.1254'>10.1001/archneur.61.8.1254</a></div></div></td></tr><tr><td><a href='/doi/10.1358/mf.2009.31.2.1338414' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>9.</div></td><td><div class='doi-body' data-key='10.1358/mf.2009.31.2.1338414'><a href='/doi/10.1358/mf.2009.31.2.1338414' class='pub-title'>The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs</a><div class='pub-body'>M.M. Castel-Branco, G.L. Alves, I.V. Figueiredo, A.C. Falcao, M.M. Caramona (2009) <i>Methods and Findings in Experimental and Clinical Pharmacology</i>. doi:<a class='pub-doi' href='https://doi.org/10.1358/mf.2009.31.2.1338414'>10.1358/mf.2009.31.2.1338414</a></div></div></td></tr><tr><td><a href='/doi/10.1016/j.seizure.2011.01.003' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>10.</div></td><td><div class='doi-body' data-key='10.1016/j.seizure.2011.01.003'><a href='/doi/10.1016/j.seizure.2011.01.003' class='pub-title'>Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs</a><div class='pub-body'>Wolfgang Löscher (2011) <i>Seizure</i>. doi:<a class='pub-doi' href='https://doi.org/10.1016/j.seizure.2011.01.003'>10.1016/j.seizure.2011.01.003</a></div></div></td></tr><tr><td><a href='/doi/10.1002/0471141755.ph0522s45' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>11.</div></td><td><div class='doi-body' data-key='10.1002/0471141755.ph0522s45'><a href='/doi/10.1002/0471141755.ph0522s45' class='pub-title'>Acute Seizure Tests in Epilepsy Research: Electroshock- and Chemical-Induced Convulsions in the Mouse</a><div class='pub-body'>William J. Giardina, Maciej Gasior (2009) <i>Current Protocols in Pharmacology</i>. doi:<a class='pub-doi' href='https://doi.org/10.1002/0471141755.ph0522s45'>10.1002/0471141755.ph0522s45</a></div></div></td></tr><tr><td><a href='/doi/10.1038/nn.3934' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>12.</div></td><td><div class='doi-body' data-key='10.1038/nn.3934'><a href='/doi/10.1038/nn.3934' class='pub-title'>Animal models in epilepsy research: legacies and new directions</a><div class='pub-body'>Brian P Grone, Scott C Baraban (2015) <i>Nature Neuroscience</i>. doi:<a class='pub-doi' href='https://doi.org/10.1038/nn.3934'>10.1038/nn.3934</a></div></div></td></tr><tr><td><a href='/doi/10.2147/NDT.S50371' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>13.</div></td><td><div class='doi-body' data-key='10.2147/NDT.S50371'><a href='/doi/10.2147/NDT.S50371' class='pub-title'>Animal models of epilepsy: use and limitations</a><div class='pub-body'>Ludmyla Kandratavicius, Priscila Balista, Cleiton Lopes-Aguiar, Rafael Ruggiero, Eduardo Umeoka, Norberto Garcia-Cairasco, Lezio Bueno-Junior, Joao Leite (2014) <i>NDT</i>. doi:<a class='pub-doi' href='https://doi.org/10.2147/NDT.S50371'>10.2147/NDT.S50371</a></div></div></td></tr><tr><td><a href='/doi/10.1136/bmj.g254' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>14.</div></td><td><div class='doi-body' data-key='10.1136/bmj.g254'><a href='/doi/10.1136/bmj.g254' class='pub-title'>Drug treatment of epilepsy in adults</a><div class='pub-body'>D. Schmidt, S. C. Schachter (2014) <i>BMJ</i>. doi:<a class='pub-doi' href='https://doi.org/10.1136/bmj.g254'>10.1136/bmj.g254</a></div></div></td></tr><tr><td><a href='/doi/10.1016/j.nurt.2006.11.009' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>15.</div></td><td><div class='doi-body' data-key='10.1016/j.nurt.2006.11.009'><a href='/doi/10.1016/j.nurt.2006.11.009' class='pub-title'>Discovery of antiepileptic drugs</a><div class='pub-body'>Misty Smith, Karen S. Wilcox, H. Steve White (2007) <i>Neurotherapeutics</i>. doi:<a class='pub-doi' href='https://doi.org/10.1016/j.nurt.2006.11.009'>10.1016/j.nurt.2006.11.009</a></div></div></td></tr><tr><td><a href='/doi/10.1016/S1474-4422(07)70215-6' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>16.</div></td><td><div class='doi-body' data-key='10.1016/S1474-4422(07)70215-6'><a href='/doi/10.1016/S1474-4422(07)70215-6' class='pub-title'>Development of new antiepileptic drugs: challenges, incentives, and recent advances</a><div class='pub-body'>Emilio Perucca, Jacqueline French, Meir Bialer (2007) <i>The Lancet Neurology</i>. doi:<a class='pub-doi' href='https://doi.org/10.1016/S1474-4422(07)70215-6'>10.1016/S1474-4422(07)70215-6</a></div></div></td></tr><tr><td><a href='/doi/10.1038/nrd2997' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>17.</div></td><td><div class='doi-body' data-key='10.1038/nrd2997'><a href='/doi/10.1038/nrd2997' class='pub-title'>Key factors in the discovery and development of new antiepileptic drugs</a><div class='pub-body'>Meir Bialer, H. Steve White (2010) <i>Nature Reviews Drug Discovery</i>. doi:<a class='pub-doi' href='https://doi.org/10.1038/nrd2997'>10.1038/nrd2997</a></div></div></td></tr><tr><td><a href='/doi/10.1038/nrd4126' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>18.</div></td><td><div class='doi-body' data-key='10.1038/nrd4126'><a href='/doi/10.1038/nrd4126' class='pub-title'>New avenues for anti-epileptic drug discovery and development</a><div class='pub-body'>Wolfgang Löscher, Henrik Klitgaard, Roy E. Twyman, Dieter Schmidt (2013) <i>Nature Reviews Drug Discovery</i>. doi:<a class='pub-doi' href='https://doi.org/10.1038/nrd4126'>10.1038/nrd4126</a></div></div></td></tr><tr><td><a href='/doi/10.1213/00000539-197707000-00010' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>19.</div></td><td><div class='doi-body' data-key='10.1213/00000539-197707000-00010'><a href='/doi/10.1213/00000539-197707000-00010' class='pub-title'>Relationship of Pre- and Postanesthetic EEG Abnormalities to Enflurane-Induced Seizure Activity</a><div class='pub-body'>KIM J. BURCHIEL, JAMES J. STOCKARD, RODERICK K. CALVERLEY, N. TY SMITH (1977) <i>Anesthesia &amp; Analgesia</i>. doi:<a class='pub-doi' href='https://doi.org/10.1213/00000539-197707000-00010'>10.1213/00000539-197707000-00010</a></div></div></td></tr><tr><td><a href='/doi/10.1212/wnl.38.6.924' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>20.</div></td><td><div class='doi-body' data-key='10.1212/wnl.38.6.924'><a href='/doi/10.1212/wnl.38.6.924' class='pub-title'>Effect of isoflurane and enflurane on the electrocorticogram of epileptic patients</a><div class='pub-body'>B. M. Ito, S. Sato, C. V. Kufta, D. Tran (1988) <i>Neurology</i>. doi:<a class='pub-doi' href='https://doi.org/10.1212/wnl.38.6.924'>10.1212/wnl.38.6.924</a></div></div></td></tr><tr><td><a href='/doi/10.1213/00000539-197001000-00001' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>21.</div></td><td><div class='doi-body' data-key='10.1213/00000539-197001000-00001'><a href='/doi/10.1213/00000539-197001000-00001' class='pub-title'>Clinical Investigation of Compound 347 (??thrane)</a><div class='pub-body'>MARTIN H. LEBOWITZ, CASEY D. BLITT, JOHN B. DILLON (1970) <i>Anesthesia &amp; Analgesia</i>. doi:<a class='pub-doi' href='https://doi.org/10.1213/00000539-197001000-00001'>10.1213/00000539-197001000-00001</a></div></div></td></tr><tr><td><a href='/doi/10.1213/00000539-199004000-00016' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>22.</div></td><td><div class='doi-body' data-key='10.1213/00000539-199004000-00016'><a href='/doi/10.1213/00000539-199004000-00016' class='pub-title'>Pro- and Anticonvulsant Effects of Anesthetics (Part II)</a><div class='pub-body'>Paul A. Modica, Rene Tempelhoff, Paul F. White (1990) <i>Anesthesia &amp; Analgesia</i>. doi:<a class='pub-doi' href='https://doi.org/10.1213/00000539-199004000-00016'>10.1213/00000539-199004000-00016</a></div></div></td></tr><tr><td><a href='/doi/10.1097/00000542-198005000-00010' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>23.</div></td><td><div class='doi-body' data-key='10.1097/00000542-198005000-00010'><a href='/doi/10.1097/00000542-198005000-00010' class='pub-title'>Diagnostic Activation of Epileptogenic Foci by Enflurane</a><div class='pub-body'>DAVID C. FLEMMING, JAMES FITZPATRICK, RUGGERO G. FARIELLO, THOMAS DUFF, DANIEL HELLMAN, BRIAN H. HOFF (1980) <i>Anesthesiology</i>. doi:<a class='pub-doi' href='https://doi.org/10.1097/00000542-198005000-00010'>10.1097/00000542-198005000-00010</a></div></div></td></tr><tr><td><a href='/doi/10.1016/0013-4694(75)90199-6' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>24.</div></td><td><div class='doi-body' data-key='10.1016/0013-4694(75)90199-6'><a href='/doi/10.1016/0013-4694(75)90199-6' class='pub-title'>American electroencephalographic society</a><div class='pub-body'>G.E. Chatrian (1975) <i>Electroencephalography and Clinical Neurophysiology</i>. doi:<a class='pub-doi' href='https://doi.org/10.1016/0013-4694(75)90199-6'>10.1016/0013-4694(75)90199-6</a></div></div></td></tr><tr><td><a href='/doi/10.1097/00000542-197111000-00006' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>25.</div></td><td><div class='doi-body' data-key='10.1097/00000542-197111000-00006'><a href='/doi/10.1097/00000542-197111000-00006' class='pub-title'>The Electroencephalographic Pattern during Anesthesia with Ethrane</a><div class='pub-body'>John L. Neigh, J Kent Garman, James R. Harp (1971) <i>Anesthesiology</i>. doi:<a class='pub-doi' href='https://doi.org/10.1097/00000542-197111000-00006'>10.1097/00000542-197111000-00006</a></div></div></td></tr><tr><td><a href='/doi/10.1097/00000542-197503000-00026' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>26.</div></td><td><div class='doi-body' data-key='10.1097/00000542-197503000-00026'><a href='/doi/10.1097/00000542-197503000-00026' class='pub-title'>Delayed Seizure Activity Following Enflurane Anesthesia</a><div class='pub-body'>Winfried W. Ohm, Bruce F. Cullen, David W. Amory, Ross D. Kennedy (1975) <i>Anesthesiology</i>. doi:<a class='pub-doi' href='https://doi.org/10.1097/00000542-197503000-00026'>10.1097/00000542-197503000-00026</a></div></div></td></tr><tr><td><a href='/doi/10.1097/00000542-197109000-00007' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>27.</div></td><td><div class='doi-body' data-key='10.1097/00000542-197109000-00007'><a href='/doi/10.1097/00000542-197109000-00007' class='pub-title'>The Biotransformation of Ēthrane in Man</a><div class='pub-body'>Robert E. Chase, Duncan A. Holaday, V. Fiserova-Bergerova, Lawrence J. Saidman, Frank E. Mack (1971) <i>Anesthesiology</i>. doi:<a class='pub-doi' href='https://doi.org/10.1097/00000542-197109000-00007'>10.1097/00000542-197109000-00007</a></div></div></td></tr><tr><td><a href='/doi/10.1007/bf03006812' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>28.</div></td><td><div class='doi-body' data-key='10.1007/bf03006812'><a href='/doi/10.1007/bf03006812' class='pub-title'>The influence of intravenous anaesthetics on enflurane-induced central nervous system seizure activity</a><div class='pub-body'>Paul C. Darimont, Leonard C. Jenkins (1977) <i>Canadian Anaesthetists’ Society Journal</i>. doi:<a class='pub-doi' href='https://doi.org/10.1007/bf03006812'>10.1007/bf03006812</a></div></div></td></tr><tr><td><a href='/doi/10.15363/thinklab.a7' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>29.</div></td><td><div class='doi-body' data-key='10.15363/thinklab.a7'><a href='/p/rephetio/report' class='pub-title'>Rephetio: Repurposing drugs on a hetnet [report]</a><div class='pub-body'>Daniel Himmelstein, Antoine Lizee, Chrissy Hessler, Leo Brueggeman, Sabrina Chen, Dexter Hadley, Ari Green, Pouya Khankhanian, Sergio Baranzini (2016) <i>Thinklab</i>. doi:<a class='pub-doi' href='https://doi.org/10.15363/thinklab.a7'>10.15363/thinklab.a7</a></div></div></td></tr><tr><td><a href='/doi/10.1101/087619' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>30.</div></td><td><div class='doi-body' data-key='10.1101/087619'><a href='/doi/10.1101/087619' class='pub-title'>Systematic integration of biomedical knowledge prioritizes drugs for repurposing</a><div class='pub-body'>Daniel S Himmelstein, Antoine Lizee, Christine Hessler, Leo Brueggeman, Sabrina L Chen, Dexter Hadley, Ari Green, Pouya Khankhanian, Sergio E Baranzini (2016) <i>Cold Spring Harbor Laboratory Press</i>. doi:<a class='pub-doi' href='https://doi.org/10.1101/087619'>10.1101/087619</a></div></div></td></tr><tr><td><a href='/doi/10.1016/j.physbeh.2008.05.020' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>31.</div></td><td><div class='doi-body' data-key='10.1016/j.physbeh.2008.05.020'><a href='/doi/10.1016/j.physbeh.2008.05.020' class='pub-title'>Acamprosate attenuates the handling induced convulsions during alcohol withdrawal in Swiss Webster mice</a><div class='pub-body'>Justin M. Farook, Ali Krazem, Ben Lewis, Dennis J. Morrell, John M. Littleton, Susan Barron (2008) <i>Physiology &amp; Behavior</i>. doi:<a class='pub-doi' href='https://doi.org/10.1016/j.physbeh.2008.05.020'>10.1016/j.physbeh.2008.05.020</a></div></div></td></tr><tr><td><a href='/doi/10.2165/00023210-200519060-00004' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>32.</div></td><td><div class='doi-body' data-key='10.2165/00023210-200519060-00004'><a href='/doi/10.2165/00023210-200519060-00004' class='pub-title'>Neuroprotective and Abstinence-Promoting Effects of Acamprosate</a><div class='pub-body'>Philippe De Witte, John Littleton, Philippe Parot, George Koob (2005) <i>CNS Drugs</i>. doi:<a class='pub-doi' href='https://doi.org/10.2165/00023210-200519060-00004'>10.2165/00023210-200519060-00004</a></div></div></td></tr><tr style=&#39;display:none;&#39;><td><a href='/doi/10.15363/thinklab.d228' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>33.</div></td><td><div class='doi-body' data-key='10.15363/thinklab.d228'><a href='/d/228' class='pub-title'>Decomposing the DWPC to assess intermediate node or edge contributions</a><div class='pub-body'>Daniel Himmelstein (2016) <i>Thinklab</i>. doi:<a href='https://doi.org/10.15363/thinklab.d228'>10.15363/thinklab.d228</a></div></div></td></tr><tr style=&#39;display:none;&#39;><td><a href='/doi/10.15363/thinklab.d229' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>34.</div></td><td><div class='doi-body' data-key='10.15363/thinklab.d229'><a href='/d/229' class='pub-title'>Decomposing predictions into their network support</a><div class='pub-body'>Daniel Himmelstein (2016) <i>Thinklab</i>. doi:<a href='https://doi.org/10.15363/thinklab.d229'>10.15363/thinklab.d229</a></div></div></td></tr><tr style=&#39;display:none;&#39;><td><a href='/doi/10.15363/thinklab.d186' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>35.</div></td><td><div class='doi-body' data-key='10.15363/thinklab.d186'><a href='/d/186' class='pub-title'>Incorporating DrugCentral data in our network</a><div class='pub-body'>Daniel Himmelstein, Oleg Ursu, Mike Gilson, Pouya Khankhanian, Tudor Oprea (2016) <i>Thinklab</i>. doi:<a href='https://doi.org/10.15363/thinklab.d186'>10.15363/thinklab.d186</a></div></div></td></tr><tr><td><a href='/doi/10.15363/thinklab.a7' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>36.</div></td><td><div class='doi-body' data-key='10.15363/thinklab.a7'><a href='/p/rephetio/report' class='pub-title'>Rephetio: Repurposing drugs on a hetnet [report]</a><div class='pub-body'>Daniel Himmelstein, Antoine Lizee, Chrissy Hessler, Leo Brueggeman, Sabrina Chen, Dexter Hadley, Ari Green, Pouya Khankhanian, Sergio Baranzini (2016) <i>Thinklab</i>. doi:<a class='pub-doi' href='https://doi.org/10.15363/thinklab.a7'>10.15363/thinklab.a7</a></div></div></td></tr><tr style=&#39;display:none;&#39;><td><a href='/doi/10.15363/thinklab.d70' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>37.</div></td><td><div class='doi-body' data-key='10.15363/thinklab.d70'><a href='/d/70' class='pub-title'>Calculating molecular similarities between DrugBank compounds</a><div class='pub-body'>Daniel Himmelstein, Sabrina Chen (2015) <i>Thinklab</i>. doi:<a href='https://doi.org/10.15363/thinklab.d70'>10.15363/thinklab.d70</a></div></div></td></tr><tr><td><a href='/doi/10.1093/nar/gkt1068' class='pub-comments tt-right' title='Article comments'>4</a></td><td><div class='pub-order'>38.</div></td><td><div class='doi-body' data-key='10.1093/nar/gkt1068'><a href='/doi/10.1093/nar/gkt1068' class='pub-title'>DrugBank 4.0: shedding new light on drug metabolism</a><div class='pub-body'>V. Law, C. Knox, Y. Djoumbou, T. Jewison, A. C. Guo, Y. Liu, A. Maciejewski, D. Arndt, M. Wilson, V. Neveu, A. Tang, G. Gabriel, C. Ly, S. Adamjee, Z. T. Dame, B. Han, Y. Zhou, D. S. Wishart (2013) <i>Nucleic Acids Research</i>. doi:<a class='pub-doi' href='https://doi.org/10.1093/nar/gkt1068'>10.1093/nar/gkt1068</a></div></div></td></tr><tr><td><a href='/doi/10.4135/9781483349985.n37' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>39.</div></td><td><div class='doi-body' data-key='10.4135/9781483349985.n37'><a href='/doi/10.4135/9781483349985.n37' class='pub-title'>Anatomical Therapeutic Chemical Classification System (WHO)</a><div class='pub-body'> (unknown) <i>The SAGE Encyclopedia of Pharmacology and Society</i>. doi:<a class='pub-doi' href='https://doi.org/10.4135/9781483349985.n37'>10.4135/9781483349985.n37</a></div></div></td></tr><tr><td><a href='/doi/10.1093/nar/gkw993' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>40.</div></td><td><div class='doi-body' data-key='10.1093/nar/gkw993'><a href='/doi/10.1093/nar/gkw993' class='pub-title'>DrugCentral: online drug compendium</a><div class='pub-body'>Oleg Ursu, Jayme Holmes, Jeffrey Knockel, Cristian G. Bologa, Jeremy J. Yang, Stephen L. Mathias, Stuart J. Nelson, Tudor I. Oprea (2016) <i>Nucleic Acids Research</i>. doi:<a class='pub-doi' href='https://doi.org/10.1093/nar/gkw993'>10.1093/nar/gkw993</a></div></div></td></tr><tr><td><a href='/doi/10.15363/thinklab.d186' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>41.</div></td><td><div class='doi-body' data-key='10.15363/thinklab.d186'><a href='/d/186' class='pub-title'>Incorporating DrugCentral data in our network</a><div class='pub-body'>Daniel Himmelstein, Oleg Ursu, Mike Gilson, Pouya Khankhanian, Tudor Oprea (2016) <i>Thinklab</i>. doi:<a href='https://doi.org/10.15363/thinklab.d186'>10.15363/thinklab.d186</a></div></div></td></tr><tr><td><a href='/doi/10.2174/156802607780636726' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>42.</div></td><td><div class='doi-body' data-key='10.2174/156802607780636726'><a href='/doi/10.2174/156802607780636726' class='pub-title'>Carbonic Anhydrase Inhibitors as Anticonvulsant Agents</a><div class='pub-body'>Anne Thiry, Jean-Michel Dogne, Claudiu Supuran, Bernard Masereel (2007) <i>Current Topics in Medicinal Chemistry</i>. doi:<a class='pub-doi' href='https://doi.org/10.2174/156802607780636726'>10.2174/156802607780636726</a></div></div></td></tr><tr><td><a href='/doi/10.1517/13543776.2013.782394' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>43.</div></td><td><div class='doi-body' data-key='10.1517/13543776.2013.782394'><a href='/doi/10.1517/13543776.2013.782394' class='pub-title'>Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review</a><div class='pub-body'>Mayank Aggarwal, Bhargav Kondeti, Robert McKenna (2013) <i>Expert Opinion on Therapeutic Patents</i>. doi:<a class='pub-doi' href='https://doi.org/10.1517/13543776.2013.782394'>10.1517/13543776.2013.782394</a></div></div></td></tr><tr style=&#39;display:none;&#39;><td><a href='/doi/10.15363/thinklab.d186' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>44.</div></td><td><div class='doi-body' data-key='10.15363/thinklab.d186'><a href='/d/186' class='pub-title'>Incorporating DrugCentral data in our network</a><div class='pub-body'>Daniel Himmelstein, Oleg Ursu, Mike Gilson, Pouya Khankhanian, Tudor Oprea (2016) <i>Thinklab</i>. doi:<a href='https://doi.org/10.15363/thinklab.d186'>10.15363/thinklab.d186</a></div></div></td></tr><tr><td><a href='/doi/10.15363/thinklab.d215' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>45.</div></td><td><div class='doi-body' data-key='10.15363/thinklab.d215'><a href='/d/215' class='pub-title'>Edge dropout contamination in hetnet edge prediction</a><div class='pub-body'>Daniel Himmelstein (2016) <i>Thinklab</i>. doi:<a href='https://doi.org/10.15363/thinklab.d215'>10.15363/thinklab.d215</a></div></div></td></tr><tr><td><a href='/doi/10.15363/thinklab.d34' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>46.</div></td><td><div class='doi-body' data-key='10.15363/thinklab.d34'><a href='/d/34' class='pub-title'>Using Entrez Gene as our gene vocabulary</a><div class='pub-body'>Daniel Himmelstein, Casey Greene, Alexander Pico (2015) <i>Thinklab</i>. doi:<a href='https://doi.org/10.15363/thinklab.d34'>10.15363/thinklab.d34</a></div></div></td></tr><tr><td><a href='/doi/10.5281/zenodo.45524' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>47.</div></td><td><div class='doi-body' data-key='10.5281/zenodo.45524'><a href='/doi/10.5281/zenodo.45524' class='pub-title'>Processed Entrez Gene datasets for humans v1.0</a><div class='pub-body'>Daniel S. Himmelstein (2016) <i>Zenodo</i>. doi:<a class='pub-doi' href='https://doi.org/10.5281/zenodo.45524'>10.5281/zenodo.45524</a></div></div></td></tr><tr><td><a href='/doi/10.1046/j.1528-1157.2001.042suppl.3008.x' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>48.</div></td><td><div class='doi-body' data-key='10.1046/j.1528-1157.2001.042suppl.3008.x'><a href='/doi/10.1046/j.1528-1157.2001.042suppl.3008.x' class='pub-title'>GABAergic Mechanisms in Epilepsy</a><div class='pub-body'>David M. Treiman (2001) <i>Epilepsia</i>. doi:<a class='pub-doi' href='https://doi.org/10.1046/j.1528-1157.2001.042suppl.3008.x'>10.1046/j.1528-1157.2001.042suppl.3008.x</a></div></div></td></tr><tr><td><a href='/doi/10.2174/157015910792246254' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>49.</div></td><td><div class='doi-body' data-key='10.2174/157015910792246254'><a href='/doi/10.2174/157015910792246254' class='pub-title'>Antiepileptic Drug Interactions - Principles and Clinical Implications</a><div class='pub-body'>Svein I. Johannessen, Cecilie Johannessen Landmark (2010) <i>Current Neuropharmacology</i>. doi:<a class='pub-doi' href='https://doi.org/10.2174/157015910792246254'>10.2174/157015910792246254</a></div></div></td></tr><tr><td><a href='/doi/10.2174/156802612800229206' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>50.</div></td><td><div class='doi-body' data-key='10.2174/156802612800229206'><a href='/doi/10.2174/156802612800229206' class='pub-title'>Sodium Channel Blockers as Therapeutic Target for Treating Epilepsy: Recent Updates</a><div class='pub-body'>Valentina Zuliani, Marco Fantini, Mirko Rivara (2012) <i>Current Topics in Medicinal Chemistry</i>. doi:<a class='pub-doi' href='https://doi.org/10.2174/156802612800229206'>10.2174/156802612800229206</a></div></div></td></tr><tr><td><a href='/doi/10.2174/1568026053386962' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>51.</div></td><td><div class='doi-body' data-key='10.2174/1568026053386962'><a href='/doi/10.2174/1568026053386962' class='pub-title'>Mechanisms of Action of Antiepileptic Drugs</a><div class='pub-body'>Piotr Czapinski, Barbara Blaszczyk, Stanislaw Czuczwar (2005) <i>Current Topics in Medicinal Chemistry</i>. doi:<a class='pub-doi' href='https://doi.org/10.2174/1568026053386962'>10.2174/1568026053386962</a></div></div></td></tr><tr><td><a href='/doi/10.1016/j.nurt.2006.11.010' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>52.</div></td><td><div class='doi-body' data-key='10.1016/j.nurt.2006.11.010'><a href='/doi/10.1016/j.nurt.2006.11.010' class='pub-title'>Molecular targets for antiepileptic drug development</a><div class='pub-body'>Brian S. Meldrum, Michael A. Rogawski (2007) <i>Neurotherapeutics</i>. doi:<a class='pub-doi' href='https://doi.org/10.1016/j.nurt.2006.11.010'>10.1016/j.nurt.2006.11.010</a></div></div></td></tr><tr><td><a href='/doi/10.1038/nrn1430' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>53.</div></td><td><div class='doi-body' data-key='10.1038/nrn1430'><a href='/doi/10.1038/nrn1430' class='pub-title'>The neurobiology of antiepileptic drugs</a><div class='pub-body'>Michael A. Rogawski, Wolfgang Löscher (2004) <i>Nature Reviews Neuroscience</i>. doi:<a class='pub-doi' href='https://doi.org/10.1038/nrn1430'>10.1038/nrn1430</a></div></div></td></tr><tr><td><a href='/doi/10.1016/j.seizure.2010.10.027' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>54.</div></td><td><div class='doi-body' data-key='10.1016/j.seizure.2010.10.027'><a href='/doi/10.1016/j.seizure.2010.10.027' class='pub-title'>Antiepileptic drug therapy the story so far</a><div class='pub-body'>Martin J. Brodie (2010) <i>Seizure</i>. doi:<a class='pub-doi' href='https://doi.org/10.1016/j.seizure.2010.10.027'>10.1016/j.seizure.2010.10.027</a></div></div></td></tr><tr><td><a href='/doi/10.1093/med/9780199746545.003.0010' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>55.</div></td><td><div class='doi-body' data-key='10.1093/med/9780199746545.003.0010'><a href='/doi/10.1093/med/9780199746545.003.0010' class='pub-title'>Glutamatergic Mechanisms Related to Epilepsy</a><div class='pub-body'>Raymond Dingledine (2012) <i>Jasper&#39;s Basic Mechanisms of the Epilepsies</i>. doi:<a class='pub-doi' href='https://doi.org/10.1093/med/9780199746545.003.0010'>10.1093/med/9780199746545.003.0010</a></div></div></td></tr><tr><td><a href='/doi/10.1007/0-387-27526-6_13' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>56.</div></td><td><div class='doi-body' data-key='10.1007/0-387-27526-6_13'><a href='/doi/10.1007/0-387-27526-6_13' class='pub-title'>Selective Permeability of Voltage-Gated Calcium Channels</a><div class='pub-body'>William A. Sather (unknown) <i>Voltage-Gated Calcium Channels</i>. doi:<a class='pub-doi' href='https://doi.org/10.1007/0-387-27526-6_13'>10.1007/0-387-27526-6_13</a></div></div></td></tr><tr><td><a href='/doi/10.1111/j.1528-1167.2010.02797.x' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>57.</div></td><td><div class='doi-body' data-key='10.1111/j.1528-1167.2010.02797.x'><a href='/doi/10.1111/j.1528-1167.2010.02797.x' class='pub-title'>Voltage-gated calcium channels in epilepsy</a><div class='pub-body'>Stuart M. Cain, Terrance P. Snutch (2010) <i>Epilepsia</i>. doi:<a class='pub-doi' href='https://doi.org/10.1111/j.1528-1167.2010.02797.x'>10.1111/j.1528-1167.2010.02797.x</a></div></div></td></tr><tr><td><a href='/doi/10.2174/156802607780636726' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>58.</div></td><td><div class='doi-body' data-key='10.2174/156802607780636726'><a href='/doi/10.2174/156802607780636726' class='pub-title'>Carbonic Anhydrase Inhibitors as Anticonvulsant Agents</a><div class='pub-body'>Anne Thiry, Jean-Michel Dogne, Claudiu Supuran, Bernard Masereel (2007) <i>Current Topics in Medicinal Chemistry</i>. doi:<a class='pub-doi' href='https://doi.org/10.2174/156802607780636726'>10.2174/156802607780636726</a></div></div></td></tr><tr><td><a href='/doi/10.1517/13543776.2013.782394' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>59.</div></td><td><div class='doi-body' data-key='10.1517/13543776.2013.782394'><a href='/doi/10.1517/13543776.2013.782394' class='pub-title'>Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review</a><div class='pub-body'>Mayank Aggarwal, Bhargav Kondeti, Robert McKenna (2013) <i>Expert Opinion on Therapeutic Patents</i>. doi:<a class='pub-doi' href='https://doi.org/10.1517/13543776.2013.782394'>10.1517/13543776.2013.782394</a></div></div></td></tr><tr><td><a href='/doi/10.2174/1568007023339193' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>60.</div></td><td><div class='doi-body' data-key='10.2174/1568007023339193'><a href='/doi/10.2174/1568007023339193' class='pub-title'>Nicotinic Acetylcholine Receptors and Epilepsy</a><div class='pub-body'>Ortrud Steinlein (2002) <i>Current Drug Target -CNS &amp; Neurological Disorders</i>. doi:<a class='pub-doi' href='https://doi.org/10.2174/1568007023339193'>10.2174/1568007023339193</a></div></div></td></tr><tr><td><a href='/doi/10.1007/s11064-007-9429-3' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>61.</div></td><td><div class='doi-body' data-key='10.1007/s11064-007-9429-3'><a href='/doi/10.1007/s11064-007-9429-3' class='pub-title'>Anticonvulsant Efficacy of Drugs with Cholinergic and/or Glutamatergic Antagonism Microinfused into Area Tempestas of Rats Exposed to Soman</a><div class='pub-body'>Trond Myhrer, Siri Enger, Pål Aas (2007) <i>Neurochemical Research</i>. doi:<a class='pub-doi' href='https://doi.org/10.1007/s11064-007-9429-3'>10.1007/s11064-007-9429-3</a></div></div></td></tr><tr><td><a href='/doi/10.1101/cshperspect.a022871' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>62.</div></td><td><div class='doi-body' data-key='10.1101/cshperspect.a022871'><a href='/doi/10.1101/cshperspect.a022871' class='pub-title'>Potassium Channels in Epilepsy</a><div class='pub-body'>Rüdiger Köhling, Jakob Wolfart (2016) <i>Cold Spring Harbor Perspectives in Medicine</i>. doi:<a class='pub-doi' href='https://doi.org/10.1101/cshperspect.a022871'>10.1101/cshperspect.a022871</a></div></div></td></tr><tr><td><a href='/doi/10.1517/14740338.2013.823399' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>63.</div></td><td><div class='doi-body' data-key='10.1517/14740338.2013.823399'><a href='/doi/10.1517/14740338.2013.823399' class='pub-title'>Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel</a><div class='pub-body'>Michele A Faulkner, Rachel A Burke (2013) <i>Expert Opinion on Drug Safety</i>. doi:<a class='pub-doi' href='https://doi.org/10.1517/14740338.2013.823399'>10.1517/14740338.2013.823399</a></div></div></td></tr><tr><td><a href='/doi/10.1136/jnnp.2006.100222' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>64.</div></td><td><div class='doi-body' data-key='10.1136/jnnp.2006.100222'><a href='/doi/10.1136/jnnp.2006.100222' class='pub-title'>Movement disorders in patients taking anticonvulsants</a><div class='pub-body'>C Zadikoff, R P Munhoz, A N Asante, N Politzer, R Wennberg, P Carlen, A Lang (2007) <i>Journal of Neurology, Neurosurgery &amp; Psychiatry</i>. doi:<a class='pub-doi' href='https://doi.org/10.1136/jnnp.2006.100222'>10.1136/jnnp.2006.100222</a></div></div></td></tr><tr><td><a href='/doi/10.1016/j.ebcr.2015.07.003' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>65.</div></td><td><div class='doi-body' data-key='10.1016/j.ebcr.2015.07.003'><a href='/doi/10.1016/j.ebcr.2015.07.003' class='pub-title'>Anticonvulsant-induced downbeat nystagmus in epilepsy</a><div class='pub-body'>Dongyan Wu, Roland D. Thijs (2015) <i>Epilepsy &amp; Behavior Case Reports</i>. doi:<a class='pub-doi' href='https://doi.org/10.1016/j.ebcr.2015.07.003'>10.1016/j.ebcr.2015.07.003</a></div></div></td></tr><tr><td><a href='/doi/10.1016/S1059-1311(03)00082-7' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>66.</div></td><td><div class='doi-body' data-key='10.1016/S1059-1311(03)00082-7'><a href='/doi/10.1016/S1059-1311(03)00082-7' class='pub-title'>The effect of antiepileptic drugs on visual performance</a><div class='pub-body'>EMMA J ROFF HILTON, SARAH L HOSKING, TIM BETTS (2004) <i>Seizure</i>. doi:<a class='pub-doi' href='https://doi.org/10.1016/S1059-1311(03)00082-7'>10.1016/S1059-1311(03)00082-7</a></div></div></td></tr><tr><td><a href='/doi/10.1016/S1388-2457(00)00411-9' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>67.</div></td><td><div class='doi-body' data-key='10.1016/S1388-2457(00)00411-9'><a href='/doi/10.1016/S1388-2457(00)00411-9' class='pub-title'>Effect of antiepileptic drugs on sleep</a><div class='pub-body'>Fabio Placidi, Anna Scalise, Maria Grazia Marciani, Andrea Romigi, Marina Diomedi, Gian Luigi Gigli (2000) <i>Clinical Neurophysiology</i>. doi:<a class='pub-doi' href='https://doi.org/10.1016/S1388-2457(00)00411-9'>10.1016/S1388-2457(00)00411-9</a></div></div></td></tr><tr><td><a href='/doi/10.1016/j.seizure.2010.12.011' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>68.</div></td><td><div class='doi-body' data-key='10.1016/j.seizure.2010.12.011'><a href='/doi/10.1016/j.seizure.2010.12.011' class='pub-title'>Gastrointestinal adverse effects of antiepileptic drugs in intractable epileptic patients</a><div class='pub-body'>Soodeh Razeghi Jahromi, Mansoureh Togha, Sohrab Hashemi Fesharaki, Masoumeh Najafi, Nahid Beladi Moghadam, Jalil Arab Kheradmand, Hadi Kazemi, Ali Gorji (2011) <i>Seizure</i>. doi:<a class='pub-doi' href='https://doi.org/10.1016/j.seizure.2010.12.011'>10.1016/j.seizure.2010.12.011</a></div></div></td></tr><tr style=&#39;display:none;&#39;><td><a href='/doi/10.15363/thinklab.d210' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>69.</div></td><td><div class='doi-body' data-key='10.15363/thinklab.d210'><a href='/d/210' class='pub-title'>Our hetnet edge prediction methodology: the modeling framework for Project Rephetio</a><div class='pub-body'>Daniel Himmelstein (2016) <i>Thinklab</i>. doi:<a href='https://doi.org/10.15363/thinklab.d210'>10.15363/thinklab.d210</a></div></div></td></tr><tr style=&#39;display:none;&#39;><td><a href='/doi/10.15363/thinklab.d34' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>70.</div></td><td><div class='doi-body' data-key='10.15363/thinklab.d34'><a href='/d/34' class='pub-title'>Using Entrez Gene as our gene vocabulary</a><div class='pub-body'>Daniel Himmelstein, Casey Greene, Alexander Pico (2015) <i>Thinklab</i>. doi:<a href='https://doi.org/10.15363/thinklab.d34'>10.15363/thinklab.d34</a></div></div></td></tr><tr style=&#39;display:none;&#39;><td><a href='/doi/10.15363/thinklab.d67' class='pub-comments tt-right zero-items' title='Article comments'>0</a></td><td><div class='pub-order'>71.</div></td><td><div class='doi-body' data-key='10.15363/thinklab.d67'><a href='/d/67' class='pub-title'>Mining knowledge from MEDLINE articles and their indexed MeSH terms</a><div class='pub-body'>Daniel Himmelstein, Alex Pankov (2015) <i>Thinklab</i>. doi:<a href='https://doi.org/10.15363/thinklab.d67'>10.15363/thinklab.d67</a></div></div></td></tr></table>

    


	</td>
	<td class="thread-sidebar">


			

      <!-- <a class="btn btn-default follow-link btn-follow btn-lg is-following tt-top full-width" title="Follow discussion" data-id="224" data-ctype="thread" data-is-following="false">&nbsp;</a> -->

      

      
        
      


				

					<div class="details">Views</div>
					<span style="font-size:20px;">133</span>

        

				
					<div class="details">Topics</div>
					<div style="margin-bottom:15px;">
		            <a href="/topics/hetionet" class="tag">Hetionet</a><a href="/topics/epilepsy" class="tag">Epilepsy</a>
					</div>
				


		
			<div class="details">Referenced by</div>
			<div style="font-size:12px;"><ul style="padding-left:16px !important;">
			
				<li>
					
					<a href='/doc/7/review' class='thread-title'><span class='inbox-icon tt-top glyphicon glyphicon-flash'></span>Report Review: Rephetio: Repurposing drugs on a hetnet</a>
				</li>
			
				<li>
					
					<a href='/d/231' class='thread-title'>Why we predicted ictogenic tricyclic compounds treat epilepsy?</a>
				</li>
			
				<li>
					
					<a href='/d/107' class='thread-title'>Integrating resources with disparate licensing into an open network</a>
				</li>
			
				<li>
					
					<a href='/d/230' class='thread-title'>Visualizing the top epilepsy predictions in Cytoscape</a>
				</li>
			
				<li>
					
					Research report: <a href='/p/rephetio/report'>Rephetio: Repurposing drugs on a hetnet</a>
				</li>
			
				<li>
					
					<a href='/d/203' class='thread-title'>Predictions of whether a compound treats a disease</a>
				</li>
			
				</ul>
			</div>
		

		
			<div class="details">Cite this as</div>
			<span style="font-size:12px;">
				Pouya Khankhanian, Daniel Himmelstein (2016) Prediction in epilepsy. <i>Thinklab.</i> doi:<a href='https://doi.org/10.15363/thinklab.d224'>10.15363/thinklab.d224</a>
			</span>
		

		<div class="details">License</div>
		<p><a rel="license" href="http://creativecommons.org/licenses/by/4.0/"><img alt="Creative Commons License" style="border-width:0;width:88px;height:31px;" src="https://i.creativecommons.org/l/by/4.0/88x31.png" /></a></p>

		<div class="details">Share</div>
		
			
				<a class="share-button fb" onclick="javascript:void(window.open('https://www.facebook.com/sharer/sharer.php?u=https%3A//thinklab.org/discussion/prediction-in-epilepsy/224','','width=600,height=460,menubar=no,status=no'));" href="#"></a>
<a class="share-button twitter" onclick="javascript:void(window.open('https://twitter.com/share?text=Prediction%20in%20epilepsy&url=https%3A//thinklab.org/discussion/prediction-in-epilepsy/224','','width=600,height=300,menubar=no,status=no'));" href="#"></a>
<a class="share-button google" onclick="javascript:void(window.open('https://plus.google.com/share?url=https%3A//thinklab.org/discussion/prediction-in-epilepsy/224','','width=510,height=460,menubar=no,status=no'));" href="#"></a>

			
		

	</td>
</tr></table>


		</div>


		
	    	<div class="footer">
<!-- <div style="background:#dedede;">
	<div class="main-centered-div text-center" style="padding:20px;">
		<h4 style="margin-bottom:0px;font-weight:bold;color:gray;">Feedback? Questions? Email us: <a href="mailto:hello@thinklab.com">hello@thinklab.com</a></h4>
	</div>
</div> -->
<div class="main-footer">
	<div class="main-centered-div">

<table class="full-width"><tr>
	<td class="footer-nav">

        <div class="foot-head">Explore</div>
        <a href="/proposals">Proposals</a><br>
        <a href="/projects">Projects</a><br>
        <a href="/publications">Article discussion</a><br>
        <a href="/discussion">All discussion</a><br>
        <a href="/topics">Topics</a><br>
        <!-- <a href="/funders">Funders</a><br> -->
        <a href="/funding">Funding opportunities</a><br>

	</td>
	<td class="footer-nav">

        <!-- <div class="foot-head">Help &amp; feedback</div>	 -->
        <!-- <div class="foot-head">Intro</div>
        <a href="/benefits/for-science">Why</a><br>
        <a href="/how-it-works">How it works</a><br>

<br> -->

        <div class="foot-head">Community</div>
        <a href="/leaderboard">Leaderboard</a><br>
        <a href="/p/meta">Thinklab Meta</a><br>
				<a href="/help/faq">Help</a><br>
				<!-- <a href="/new-project">Start a proposal</a><br> -->
        <!-- <a href="/benefits/proposal">Benefits</a><br> -->
        <!-- <a href="/funding">Get funded</a><br> -->
        <!-- <a href="/participate">Become a contributor</a><br> -->
        <!-- <a href="/for-funders">For science funders</a><br> -->
        <!-- <a href="/for-institutions">For institutions</a><br> -->

	</td>
	<td class="footer-nav">



        <div class="foot-head">About</div>
        <a href="/about">Overview</a><br>
        <a href="/benefits">Benefits</a><br>
        <a href="/how-it-works">How it works</a><br>
        <a href="/about/story">Our story</a><br>
        <a href="/blog">Our blog</a><br>
        <a href="/about/jobs">Join the team</a><br>
        <br>

        <!-- <div class="foot-head">Help</div>
        <a href="/help">Help</a><br>
		 -->


	</td>
	<td class="footer-nav">
		<!-- <a href="http://twitter.com/thinklab" class="social-icon"><img src="https://think-lab.s3.amazonaws.com/s/img/icons/twitter_com.png" width="40"/></a>
		<a href="https://www.facebook.com/pages/Thinklab/310895039088185" class="social-icon"><img src="https://think-lab.s3.amazonaws.com/s/img/icons/facebook_com.png" width="40"/></a>
		<a href="https://plus.google.com/115578983466800753402/" class="social-icon"><img src="https://think-lab.s3.amazonaws.com/s/img/icons/plus_google_com.png" width="40"/></a>
		<a href="https://www.linkedin.com/company/thinklab-co" class="social-icon"><img src="https://think-lab.s3.amazonaws.com/s/img/icons/linkedin_com.png" width="40"/></a> -->
		<br><br>
		<span class="light" style='font-size:12px;'>&copy; 2015 Thinklab</span>

	</td>

</tr></table>

</div>
</div>
</div>

		

	</div>


  <script></script>
  <script>
  var MEDIA_URL = 'https://think-lab.s3.amazonaws.com/m/';
  var STATIC_URL = 'https://think-lab.s3.amazonaws.com/s/';
  var page_is_authenticated = false;
  var page_page = 'discussion';
  var page_profile_id = undefined;
</script>



	<!-- Note different script type. MUST come before MathJax.js -->
	<script type="text/x-mathjax-config">
	    MathJax.Hub.Config({
	        "HTML-CSS": { preferredFont: "TeX", availableFonts: ["STIX","TeX"],
	                        scale: 110, linebreaks: { automatic:true },
	                        EqnChunk: (MathJax.Hub.Browser.isMobile ? 10 : 50) },
	        tex2jax: { inlineMath: [ ["$$", "$$"], ["\\(","\\)"] ],
	                    displayMath: [ ["$$$","$$$"], ["\\[", "\\]"] ],
	                    processEscapes: true,}
	            });

	</script>
    <script src="https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>





  <script src="https://code.jquery.com/jquery-1.10.2.min.js"></script>
  <script src="https://code.jquery.com/ui/1.11.4/jquery-ui.min.js"></script>
  <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.6/js/bootstrap.min.js" integrity="sha384-0mSbJDEHialfmuBBQP6A4Qrprq5OVfW37PRR3j5ELqxss1yVqOtnepnHVP9aJ7xS" crossorigin="anonymous"></script>
  <script src="https://think-lab.s3.amazonaws.com/s/dist/main.min.js"></script>
  



  
	
  
  
  
<script>
$(function() {
  recordHit('thread', 224);
});
</script>



</body>
</html>
